Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20010018422 A1
Publication typeApplication
Application numberUS 09/756,593
Publication dateAug 30, 2001
Filing dateJan 8, 2001
Priority dateJul 8, 1998
Also published asCA2332641A1, CN1312817A, EP1093460A1, US5985837, WO2000002906A1
Publication number09756593, 756593, US 2001/0018422 A1, US 2001/018422 A1, US 20010018422 A1, US 20010018422A1, US 2001018422 A1, US 2001018422A1, US-A1-20010018422, US-A1-2001018422, US2001/0018422A1, US2001/018422A1, US20010018422 A1, US20010018422A1, US2001018422 A1, US2001018422A1
InventorsKurt Ritter, Bernd Janssen, Andreas Haupt, Andreas Kling, Teresa Barlozzari, Wilhelm Amberg
Original AssigneeBasf Aktiengesellschaft
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Dolastatin 15 derivatives
US 20010018422 A1
Abstract
Compounds of the present invention include cell growth inhibitors which are peptides of Formula I
A-B-D-E-F-G (I)
and acid salts thereof, wherein A, D, and E are α-amino acid residues, B is an α-amino acid residue or an α-hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sultoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
Images(43)
Previous page
Next page
Claims(21)
We claim:
1. A compound of the formula
A-B-D-E-F-G,
or a salt thereof with a pharmaceutically acceptable acid, wherein
A is a proline derivative of Formula IIa,
wherein na is 0 to 3; Ra is hydrogen, or unsubstituted or fluorine-substituted normal, branched or cyclic C1-C3-alkyl; R1 a is hydrogen, C1-C 3-alkyl, phenyl, or substituted phenyl; or Ra and R1 a together form a propylene bridge; and R2 a, R3 a, R4 a and R5 a are each, independently, hydrogen or alkyl; or
an α-amino acid derivative of Formula IIIa,
wherein Ra is hydrogen or unsubstituted or fluorine-substituted C1-C3-alkyl; R1 a is hydrogen or C1-C4-alkyl; R6 a is alkyl, substituted alkyl, alkenyl, phenyl or substituted phenyl; or R1 a is an alkyl group and R6 a is C1-C6-alkyl, cycloalkylmethyl, benzyl or substituted benzyl; and R7 a is hydrogen or alkyl; or
an α-amino acid derivative of Formula IVa,
wherein ma is 1 or 2; R7 a is hydrogen or alkyl; Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or
an α-amino acid derivative of Formula Va,
wherein R7 a is hydrogen or alkyl and Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or
an α-amino acid of Formula VIa,
wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; R1 a is hydrogen, alkyl, phenyl, or substituted phenyl; or Ra and R1 a together form a propylene bridge; and Xa is hydroxy, alkoxy or fluorine; or
an α-amino acid of Formula VIIa,
wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; R1 a is hydrogen, alkyl, phenyl, or substituted phenyl; or Ra and R1 a together form a propylene bridge; and R2 a, R3 a, R4 a and R5 a are each, independently, hydrogen or alkyl; or
an α-amino acid residue of Formula VIIIa,
wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or
a 2-azabicyclo[2.2.1]heptane-3-carboxylic acid derivative of Formula IXa,
wherein the 3-carbonyl moiety is in the endo or exo position, Za is a single bond or a double bond, and Ra is hydrogen or unsubstituted or fluorine-substituted alkyl; or
an α-amino acid residue of Formula Xa,
wherein na is 1, 2 or 3, and R7 a is hydrogen or alkyl and Ra is hydrogen , unsubstituted alkyl or fluorine-substituted alkyl;
B is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2-tert-butylglycyl or 2-ethylglycyl residue; or
an α-amino acid residue of Formula IIb,
wherein R1 b is hydrogen, and R2 b is alkyl or alkenyl; or R1 b and R2 b together form an isopropylidene group;
D is an N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkyl-2-tert-butylglycyl, N-alkylnorleucyl, N-alkylisoleucyl, N-alkyl-allo-isoleucyl or N-alkylnorvalyl residue; or
an α-amino acid residue of Formula IId,
wherein Rd is hydrogen, or unsubstituted or fluorine-substituted alkyl; R1 d is hydrogen; and R2 d is alkyl, substituted alkyl or alkenyl; or R1 d and R2 d together form an isopropylidene group; or
an α-amino acid residue of Formula IIId,
wherein nd is 1 or 2; R3 d is hydrogen, alkyl or fluorine-substituted alkyl; and Xd is hydrogen; or nd is 1 and Xd is fluorine, hydroxy, methoxy, or ethoxy;
E is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl,or hydroxyprolyl residue; or
an α-amino acid residue of Formula IIe,
wherein ne is 0, 1 or 2, R1 e is hydrogen, or unsubstituted or fluorine-substituted alkyl; R2 e and R3 e are each, independently, hydrogen or alkyl; R4 e is hydrogen, hydroxy or alkoxy; and R5 e is hydrogen or fluorine; or ne is 1 and R3 e and R4 e together form a double bond; or ne is 1 and R4 e and R5 e together form a double-bonded oxygen diradical; or ne is 1 or 2 and R1 e and R2 e together form a double bond; or
an aminocyclopentanecarboxylic acid residue of Formula IIIe,
wherein Re is alkyl and R1 e is hydrogen, or unsubstituted or fluorine-substituted alkyl;
F is an aminobenzoyl derivative of Formula IIf,
wherein Rf is a hydrogen atom or an alkyl group; the carbonyl group is ortho, meta, or para to the nitrogen atom; R1 f and R2 f are each, independently, a hydrogen atom; a halogen atom; a C1-C4-alkyl group; a methoxy, ethoxy, trifluoromethyl, nitro, cyano, amino or dimethyalmino group; or R1 f and R2 f can together form a dioxymethylene group; or
F is an aminocycloalkanecarboxylic acid residue of Formula IIIf,
wherein Rf is a hydrogen atom or an alkyl group; af is 0, 1 or 2; and the carbonyl group is in position 2 or position 3 of the cycloalkane ring relative to the nitrogen atom; and
G is a substituted or unsubstituted amino, hydrazido, aminoxy, oximato, arylalkyl, heteroarylalkyl, aryl, heteroaryl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonylalkyl, aminocarbonyl, alkylcarbonylalkyl, alkylcarbonyl, arylcarbonylalkyl, arylcarbonyl, alkylsulfinylalkyl, alkylsulfinyl, arylsulfinylalkyl, arylsulfinyl, alkylsulfonylalkyl, alkylsulfonyl, arylsulfonylalkyl or arylsulfonyl group.
2. The compound of
claim 1
wherein the pharmaceutically acceptable acid is hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid or acetylglycine.
3. The compound of
claim 1
wherein G is a monovalent radical of Formula IIg,
wherein
R1 l is a hydrogen atom, a normal or branched, saturated or unsaturated C1-C18-alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryl-C1-C6-alkoxy group, a substituted or unsubstituted aryloxy-C1-C6-alkoxy group, wherein the aryl substituents comprise one or more halogen atoms or one or more C1-C4-alkyl, methoxy, ethoxy, trifluoromethyl, nitro or dioxymethylene groups; or a heteroaryl-C1-C6-alkoxy group, wherein the heteroaryl group is derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine; and
R2 l is a hydrogen atom, a normal or branched C1-C18-alkyl group, a normal C1-C18 alkenyl group, a C3-C10-cycloalkyl group, an aryl group, or a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms, or one or more alkyl, alkoxy, dioxymethylene, trifluoromethyl or nitro groups; or a heteroaryl or substituted heteroaryl group derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
a monovalent radical of Formula IIl,
wherein al is 0, 1, 2, 3, 4, or 5; R3 l is a methyl, ethyl, normal propyl or isopropyl group; R4 l is a saturated or partially unsaturated carbocyclic system which contains from 3 to 10 carbon atoms, an aryl group, or a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, dioxymethylene, trifluoromethyl, nitro, cyanof C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a substituted or unsubstituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline, and the heteroaryl group substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
a monovalent radical of Formula IIIl,
—(CH2)2-Wl-R5 l  (IIIl),
wherein Wl is an NR6 l group, an oxygen atom or a sulfur atom, R5 l and R6 l are each, independently, a hydrogen atom or a C1-C4-alkyl, C3-C7-cycloalkyl, aryl, arylmethyl or substituted aryl or arylmethyl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, dioxymethylene, trifluoromethyl, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or R6 l is a C1-C18-alkanoyl or benzoyl group; or
a monovalent radical of Formula IVl,
—(CH2)b l -Zl  (IVl),
bl is 2, 3, or 4 and Zl is a formyl, aminocarbonyl, hydrazinocarbonyl, cyclic acetal, cyclic thioacetal, acyclic acetal or acyclic thioacetal group; or
a monovalent radical of Formula Vl,
bl is 2, 3, or 4; R7 l is a polyglycol group of the formula —O—(CH2—CH2—O)dl—CH3; and dl is between about 2 and about 4, or between about 40 and about 90; or
a monovalent radical of Formula VIl,
wherein R8 l is a hydrogen atom, or a C1-C4 alkanoyl, C1-C4 alkyl, benzoyl, or benzyl group.
4. The compound of
claim 1
wherein G is a β-hydroxy amino group of Formula IIIg,
R9 l is a hydrogen atom, or a C1-C6-alkyl, aryl or substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; and R10 l is a hydrogen atom, a methyl group or a phenyl group.
5. The compound of
claim 1
wherein G is a hydrazido group of Formula IVg,
wherein R11 l is a hydrogen atom and R12 l is a hydrogen atom, a normal or branched C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, an aryl-C1-C4-alkyl group, an aryl group, a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a heteroaryl group, a heteroaryl-C1-C4-alkyl group or a substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups.
6. The compound of
claim 1
wherein G is a monovalent radical of the formula —O—R13 l or of the formula —S—R13 l, and R13 l is a C3-C10-cycloalkyl, straight-chain or branched C2-C16-alkenylmethyl, C1-C16-alkyl or halogen-substituted C1-C16-alkyl group; R13 l is a monovalent radical of the formula —(CH2)el—R14 l, el is 1, 2, or 3, and R14 l is a saturated or partially unsaturated C3-C10 carbocyclic group; R13 l is a monovalent radical of the formula —[CH2—CH═C(CH3)— CH2]fl—H, and fl is 1, 2, 3, or 4; R13 l is a monovalent radical of the formula —[CH2—CH2—O]gl—CH3, and gl is between about 2 and about 4, or between about 40 and about 90; R13 l is a monovalent radical of the formula —(CH2)hl—X, hl is 0, 1, 2, or 3; and X is an aryl or substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; R13 l is a monovalent radical of the formula —(CH2)bl-Wl-R5 l, bl is 2, 3, or 4, Wl is an oxygen atom, a sulfur atom or an NR6 l group; R5 l is a saturated carbocyclic system which contains from about 3 to about 10 carbon atoms, a partially unsaturated carbocyclic system containing from about 3 to about 10 carbon atoms, an aryl or substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; and R6 l is a hydrogen atom, or a C1-C4 alkyl, C3-C7 cycloalkyl, C1-C18-alkanoyl, benzoyl, arylmethyl, aryl or substituted aryl or arylmethyl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups.
7. The compound of
claim 1
wherein G is an aminoxy group of the formula —O—N(R16 l)(R15 l), wherein
R15 l and R16 l are each, independently, a hydrogen atom, a normal or branched C1-C8 alkyl group, a halogen-substituted normal or branched C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4 alkyl group, an aryl-C1-C4-alkyl group, an aryl group or a substituted aryl-C1-C4-alkyl or aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
R15 l and R16 l together with the nitrogen atom form a heterocyclic ring structure comprising 5, 6, or 7 atoms.
8. The compound of
claim 1
wherein G is a oximato group of the formula —O—N═C(R15 l)(R16 l), wherein
R15 l and R16 l are each, independently, a hydrogen atom, a normal or branched C1-C8 alkyl group, a halogen-substituted normal or branched C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4 alkyl group, an aryl-C1-C4-alkyl group, an aryl group or a substituted aryl-C1-C4-alkyl or aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
R15 l and R16 l, together with the carbon atom, form a cyclic system, a cyclic system fused to an aromatic ring system or a cyclic system selected from the group consisting of:
9. The compound of
claim 1
wherein G is a hydrogen atom, a normal or branched C1-C8-alkyl group, a halogen-substituted normal or branched C1-C8-alkyl group, a C3-C8 cycloalkyl group, or a C3-C8-cycloalkyl-C1-C4-alkyl group.
10. The compound of
claim 1
wherein G is a monovalent radical of Formula Vg,
—(CH2)a g —R17 l  (Vg)
ag is 0, 1, or 2, and R17 l is an aryl group or a substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups
11. The compound of
claim 1
wherein G is a monovalent radical of Formula VIg,
bg is 0, 1, 2, or 3; eg is 0 or 1; R18 l is a hydrogen atom, a normal or branched C1-C8-alkyl group, a halogen substituted normal or branched C1-C 8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C 1-C4-alkyl group, an aryl group or a substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups.
12. The compound of
claim 1
wherein G is a monovalent radical of Formula VIIg,
dg is 0, 1, 2, or 3; eg is 0 or 1; R19 l and R20 l are, independently, a hydrogen atom, a normal or branched C1-C8-alkyl group, a halogen-substituted C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C 8-cycloalkyl-C1-C4-alkyl group, an aryl group or a substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or R19 l, R20 l and the nitrogen atom form a ring system comprising 6 or fewer carbon atoms.
13. The compound of
claim 1
wherein G is an alkylene sulfoxide or an alkylene sulfone of Formula VIIIg,
gg is 1 or 2, hg is 1 or 2, and R21 l is a methyl, trifluoromethyl, ethyl or phenyl group.
14. A compound of the formula
A-B-D-E-F-G
wherein A is N,N-dimethylvalyl, B is tertiary-leucyl, D is N-methylvalyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and C is a monovalent radical.
15. A compound of the formula
A-B-D-E-F-G
wherein A is N,N-dimethylvalyl, B is valyl, D is N-methyl-tertiaryleucyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and G is a monovalent radical.
16. A compound of the formula
A-B-D-E-F-G
wherein A is N-methyl-d-prolyl, B is valyl, D is N-methylvalyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and G is a monovalent radical.
17. A compound of the formula
A-B-D-E-F-G
wherein A is N-methylhomoprolyl, B is valyl, D is N-methylvalyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and G is a monovalent radical.
18. A compound of the formula Me2Val-Val-MeVal-Pro-F-G,
wherein F is of Formula IIf and Rf is a hydrogen atom or a methyl group, R1 f and R2 f are each a hydrogen atom, an alkyl group or an alkoxy group, and G is an amino group, an N-substituted amino group, a hydrazido, an alkyl, cycloalkyl, aryl, or alkylaryl, an alkylene ester, an alkylene amide, an alkylene sulfoxide or an alkylene sulfone group or a monovalent radical of the formula —O—R13 l or —S—R13 l, and R13 l is an alkyl, aryl or alkylaryl group.
19. A compound of the formula Me2Val-Val-MeVal-Pro-F-G,
wherein F is of Formula IIIf, Rf is a hydrogen atom or a methyl group, af is 1 or 2, and G is an amino group, an N-substituted amino group, a hydrazido, an alkyl, cycloalkyl, aryl, or alkylaryl, an alkylene ester, an alkylene amide, an alkylene sulfoxide or an alkylene sulfone group or a monovalent radical of the formula —O—R13 l or —S—R13 l, and R13 l is an alkyl, aryl or alkylaryl group.
20. A method for treating cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of
claim 1
.
21. The method of claim 45 wherein the mammal is a human.
Description
    RELATED APPLICATION(S)
  • [0001]
    This application is a continuation of International Application No. PCT/US99/14099, which designated the United States and was filed on Jun. 23, 1999, published in English, which is a continuation of, and claims priority to, Ser. No. 09/112,249, filed Jul. 8, 1998, the teachings of which are incorporated herein by reference in their entirety.
  • BACKGROUND OF THE INVENTION
  • [0002]
    A number of short peptides with significant activity as inhibitors of cell growth have been isolated from the Indian Ocean sea hare Dolabella auricularia (Bai, et al., Biochem. Pharmacology 40: 1859-1864 (1990); Beckwith et al., J. Natl. Cancer Inst. 85: 483-488 (1993) and references cited therein). These include Dolastatins 1-10 (U.S. Pat. No. 4,816,444, issued to Pettit et al.) and Dolastatin-15 (European Patent Application No. 398558). Dolastatin 15, for example, markedly inhibits the growth of the National Cancer Institute's P388 lymphocytic leukemia (PS system) cell line, a strong predictor of efficacy against various types of human malignancies.
  • [0003]
    The exceedingly small amounts of the various Dolastatin peptides present in Dolabella auricularia (about 1 mg each per 100 kg sea hare) and the consequent difficulties in purifying amounts sufficient for evaluation and use, have motivated efforts toward the synthesis of these compounds (Roux et al., Tetrahedron 50: 5345-5360 (1994); Shioiri et al., Tetrahedron 49: 1913-24 (1993); Patino et al., Tetrahedron 48: 4115-4122 (1992) and references cited therein). Synthetic Dolastatin 15, however, suffers from drawbacks which include poor solubility in aqueous systems and the need for expensive starting materials for its synthesis. These, in turn, have led to the synthesis and evaluation of structurally modified Dolastatin 15 derivatives (see, for example, Bioorg. Med. Chem. Lett. 4: 1947-50 (1994); WO 93 03054; JP-A-06234790).
  • [0004]
    However, there is a need for synthetic compounds with the biological activity of Dolastatin 15 which have useful aqueous solubility and can be produced efficiently and economically.
  • SUMMARY OF THE INVENTION
  • [0005]
    Compounds of the present invention include cell growth inhibitors which are peptides of Formula I
  • A-B-D-E-F-G (I)
  • [0006]
    and acid salts thereof, wherein A, D, and E are α-amino acid residues, B is an α-amino acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone.
  • [0007]
    Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.
  • [0008]
    An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
  • [0009]
    The present invention provides compounds with antineoplastic activity as well as increased metabolic stability relative to Dolastatin 15.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0010]
    The present invention relates to peptides having antineoplastic activity. It also includes pharmaceutical compositions comprising these compounds and methods for treating cancer in a mammal, including a human, by administration of these compositions to the mammal.
  • [0011]
    The invention is based on the discovery that Dolastatin 15, a peptide isolated from the sea hare Dolabella auricularia, is a potent inhibitor of cell growth. This compound, however, is present in trace quantities in the sea hare, and is, thus, difficult to isolate and expensive to synthesize and suffers from poor aqueous solubility. As shown herein, however, Dolastatin 15 can serve as a starting point for the development of compounds which overcome these disadvantages while retaining antineoplastic activity or exhibiting greater antineoplastic activity than the natural product. Applicants have discovered that certain structural modifications of Dolastatin 15 provide compounds with a surprisingly improved therapeutic potential for the treatment of neoplastic diseases as compared to Dolastatins-10 and -15. The Dolastatin-15 derivatives exhibit activity even in multiple drug-resistant tumor systems and an unpredicted high solubility in aqueous solvents. Furthermore, the compounds of the present invention can be conveniently synthesized, as described below in detail.
  • [0012]
    For the purposes of the present invention, the term “monovalent radical” is intended to mean an electrically neutral molecular fragment capable of forming one covalent bond with a second neutral molecular fragment. Monovalent radicals include the hydrogen atom, alkyl groups, such as methyl, ethyl and propyl groups, halogen atoms, such as fluorine, chlorine and bromine atoms, aryl groups, such as phenyl and naphthyl groups, and alkoxy groups, such as methoxy and ethoxy groups. Two monovalent radicals on adjacent sigma-bonded atoms can also together form a pi bond between the adjacent atoms. Two monovalent radicals may also be linked together, for example, by a polymethylene unit, to form a cyclic structure. For example, in the unit —N(R)R′, R and R′ are each a monovalent radical, and can, together with the nitrogen atom, form a heterocyclic ring. In addition, two monovalent radicals bonded to the same atom can also together form a divalent radical, such as an alkylidene group, for example, a propylidene group, or an oxygen atom.
  • [0013]
    For the purposes of the present invention, the term “residue” refers to the molecular fragment remaining after the removal of the elements of a water molecule (one oxygen atom, two hydrogen atoms) from a molecule, such as an amino acid or a hydroxy acid.
  • [0014]
    For the purposes of the present invention the term “normal alkyl” refers to an unbranched, or straight chain, alkyl group, for example, normal propyl (n-propyl, —CH2CH2CH3).
  • [0015]
    The compounds of the present invention can be represented by Formula I,
  • A-B-D-E-F-G (I),
  • [0016]
    wherein A, D and E are α-amino acid residues; B is an α -amino acid residue or an α-hydroxy acid residue; F is an aminobenzoic acid residue, or an aminocycloalkanecarboxylic acid residue, such as an aminocyclobutanecarboxylic acid residue, an aminocylopentanecarboxylic acid residue, or an aminocyclohexanecarboxylic acid residue; and G is a monovalent radical.
  • [0017]
    The peptides of Formula I are generally composed of L-amino acids but they can contain one or more D-amino acids. They can also be present as salts with physiologically-compatible acids, including hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.
  • [0018]
    The following is a description of the present invention, including a detailed description of individual components and of methods of using the claimed compounds.
  • Compounds of the Present Invention
  • [0019]
    Identity of A
  • [0020]
    In one embodiment, A is an amino acid derivative of Formula IIa,
  • [0021]
    where na is an integer, preferably 0, 1, 2, or 3. Ra is a monovalent radical, such as a hydrogen atom or a C1-C3-alkyl group which can be normal, branched or cyclic and can be substituted by one or more, preferably 1 to about 3, fluorine atoms; suitable examples include methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-2-fluoroethyl, 1-fluoromethyl-2-fluoroethyl or cyclopropyl; methyl, ethyl or isopropyl are preferred;
  • [0022]
    In this embodiment, R1 a is a monovalent radical, such as a hydrogen atom or a methyl, ethyl, propyl or phenyl group. The phenyl group can be substituted; suitable substituents include one or more halogen atoms, with fluorine, chlorine and bromine being preferred, C1-C4-alkyl groups, methoxy, ethoxy, trifluoromethyl or nitro groups.
  • [0023]
    R2 a, R3 a, R4 a and R5 a are each, independently, a monovalent radical, such as a hydrogen atom or a methyl group. Ra and R1 a together can also form a propylene bridge.
  • [0024]
    In another embodiment, A is an amino acid derivative of Formula IIIa,
  • [0025]
    where Ra has the meaning stated for Formula IIa, R1 a is a monovalent radical, for example, a hydrogen atom or a lower alkyl group, preferably a methyl, ethyl or propyl group.
  • [0026]
    In this embodiment, R6 a is a monovalent radical, such as a hydrogen atom, a normal or branched C1-C8-alkyl group, which can he substituted by one or more halogen, preferably fluorine, atoms, or a C3-C8-cycloalkyl or C3-C8-cycloalkyl-C 1-C4-alkyl group, a C1-C4-oxoalkyl group such as a methoxymethyl, 1-methoxyethyl or 1,1-dimethylhydroxymethyl group, a C2-C5 alkenyl group, such as a vinyl or 1-methylvinyl group, or a substituted or unsubstituted phenyl group. Suitable phenyl substituents include one or more halogen atoms, preferably fluorine, chlorine or bromine atoms, and alkyl, methoxy, ethoxy, trifluoromethyl, or nitro groups. R7 a is a monovalent radical, preferably a methyl group or an ethyl group.
  • [0027]
    In another embodiment, A is an amino acid residue of Formula IVa,
  • [0028]
    where ma is an integer, preferably 1 or 2. Ra and R7 a have the meanings stated for Ra and R7 a in Formula IIIa.
  • [0029]
    In another embodiment, A is an amino acid residue of Formula Va,
  • [0030]
    where Ra and R7 a have the meanings stated for Ra and R7 a in Formula IIIa.
  • [0031]
    In a further embodiment, A is a substituted proline derivative of Formula VIa,
  • [0032]
    where Ra and R1 a have the meanings stated for Ra and R1 a in Formula IIa, and Xa is a monovalent radical, preferably a hydroxyl, methoxy or ethoxy group or a fluorine atom.
  • [0033]
    In another embodiment, A is a thiaprolyl derivative of Formula VIIa,
  • [0034]
    where Ra, R1 a, R2 a, R3 a, R4 a and R5 a have the meanings stated for these variables in Formula IIa.
  • [0035]
    In another embodiment, A is a 1,3-dihydroisoindole derivative of Formula VIIIa,
  • [0036]
    where Ra has the meaning stated for Ra in Formula IIa.
  • [0037]
    In another embodiment, A is a 2-azabicyclo[2.2.1]heptane-3-carboxylic acid derivative of Formula IXa,
  • [0038]
    where Za is a single or double bond and Ra has the meaning stated for this variable in Formula IIa. The 3-carbonyl substituent can have either the exo or endo orientation.
  • [0039]
    Identity of B
  • [0040]
    B is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2-tert-butylglycyl or 2-ethylglycyl residue. B can also be a carboxylic acid derivative of Formula IIb,
  • [0041]
    wherein R1 b and R2 b are each a monovalent radical. R1 b is, preferably, a hydrogen atom and R2 b is, for example, a cyclopropyl group, a normal or branched butyl, preferably tertiary-butyl, group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group. Additionally, R1 b and R2 b together can be an isopropylidene group.
  • [0042]
    Identity of D
  • [0043]
    D is an N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkyl-2-tert-butylglycyl, N-alkyl-norleucyl, N-alkyl-isoleucyl, N-alkyl-allo-isoleucyl or N-alkyl-norvalyl residue, where the alkyl group is preferably methyl or ethyl.
  • [0044]
    In another embodiment, D is an α-amino carboxylic acid derivative of Formula IId,
  • [0045]
    where Rd has the meaning stated for Ra in Formula IIIa, R1 d is a monovalent radical, preferably a hydrogen atom, and R2 is a monovalent radical such as a cyclopropyl group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group. Additionally, R1 d and R2 d together can form an isopropylidene group.
  • [0046]
    Alternatively, D can be a proline derivative of Formula IIId,
  • [0047]
    where nd is an integer, for example, 1 or 2. and R3 d has the meaning stated for R1 a in Formula IIIa. Xd is a monovalent radical, preferably a hydrogen atom, and, in the case where nd equals 1, can also be a hydroxyl, methoxy or ethoxy group or a fluorine atom.
  • [0048]
    Identity of E
  • [0049]
    E is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl or hydroxyprolyl residue, or a cyclic α-amino carboxylic acid residue of Formula IIe,
  • [0050]
    where ne is an integer, preferably 0, 1 or 2. R1 e has the meaning stated for R1 a in Formula IIIa. R2 e and R3 e are each a monovalent radical, and can be, independently, a hydrogen atom or a methyl group. R4 e is a monovalent radical, preferably a hydrogen atom, a hydroxyl, methoxy or ethoxy group or a fluorine atom. R5 e is a monovalent radical, preferably a hydrogen atom. In the case where ne has the value 1, R3 e and R4 e together can form a double bond or R4 e and R5 e can together be a double-bonded oxygen radical. In the case where ne has the value 1 or 2, R1 e and R2 e can together form a double bond.
  • [0051]
    In another embodiment, E is a 2- or 3-amino-cyclopentanecarboxylic acid residue of Formula IIIe,
  • [0052]
    where Re is a monovalent radical, such as a methyl or ethyl group and R1 e has the meaning stated for R1 a in Formula IIIa.
  • [0053]
    Identity of F
  • [0054]
    In one embodiment, F is an aminobenzoyl derivative of Formula IIf,
  • [0055]
    where Rf is a hydrogen atom or an alkyl group, preferably a methyl, ethyl or propyl group. The carbonyl group can be in position 1 (ortho), 2 (meta), or 3 (para) of the phenyl ring relative to the nitrogen atom. R1 f and R2 f are each, independently, a hydrogen atom; a halogen atom, for example, a fluorine, chlorine, bromine, or iodine atom; a C1-C4-alkyl group; a methoxy, ethoxy, trifluoromethyl, nitro, cyano, amino or dimethyalmino group. Additionally, R1 f and R2 f can together form a dioxymethylene group.
  • [0056]
    In another embodiment, F is an aminocycloalkanecarboxylic acid residue of Formula IIIf,
  • [0057]
    where Rf is a monovalent radical, such as a hydrogen atom or a lower alkyl group, preferably a methyl, ethyl or propyl group. af is an integer, for example, 0, 1 or 2. The carbonyl group is in position 2 or position 3 of the cycloalkane ring relative to the nitrogen atom at position 1. The stereogenic centers can be, independently of each other, R or S. For a five-membered ring (af=1) , the combinations R1,S2 and S1,R2 would be referred to as cis-pentacin derivatives, while the combinations R1,R2 and S1,S2 are trans-pentacin derivatives.
  • [0058]
    Identity of G
  • [0059]
    In one embodiment, G is an amino or substituted amino group of Formula IIg,
  • [0060]
    where R1 l is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated C1-C18-alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryl-C1-C6-alkoxy group, or a substituted or unsubstituted aryloxy-C1-C6-alkoxy or heteroaryl-C1-C6-alkoxy group. The aryl group is preferably a phenyl or naphthyl group. The heteroaryl group is a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system, such as, for example, imidazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, pyrazolyl, thiophenyl, furanyl, pyrrolyl, 1,2,4- or 1,2,3-triazolyl, pyrazinyl, indolyl, benzofuranyl, benzothiophenyl, isoindolyl, indazolyl, quinolinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzopyranyl, benzothiazolyl, oxadiazolyl, thiadiazolyl or pyridinyl group. Suitable aryl or heteroaryl substituents include one or more halogen atoms, preferably fluorine, bromine or chlorine; C1-C4-alkyl groups; methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group or a nitro group.
  • [0061]
    R2 l is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated C1-C18-alkyl group, a C3-C10-cycloalkyl group, a substituted or unsubstituted aryl group, where aryl is preferably phenyl or naphthyl. Suitable aryl substituents include one or more halogen, preferably fluorine, chlorine or bromine, atoms, C1-C4-alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group, nitro or cyano groups, a C1-C7-alkoxycarbonyl group, a C1-C7-alkylsulfonyl group, an amino or C1-C7-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle, or an unsubstituted or substituted heteroaryl group. The heteroaryl group can be a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system which can be fused to a benzene ring, such as, for example, imidazolyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, oxazolyl, pyrazolyl, 1,2,4- or 1,2,3-triazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzopyranyl, indolyl, isoindolyl, indazolyl or quinolinyl group, with preferred substituents being C1-C6-alkyl groups, or hydroxyl or phenyl groups.
  • [0062]
    R2 l can additionally be of Formula IIl,
  • [0063]
    wherein al is an integer, preferably 0, 1, 2, 3, 4, or 5. R3 l is a monovalent radical, such as a lower alkyl group, for example, a methyl, ethyl, propyl or isopropyl group. R4 l is a saturated or partially unsaturated carbocyclic group containing from 3 to about 10 carbon atoms, or a substituted or unsubstituted aryl or heteroaryl group, where the preferred aryl and heteroaryl groups and suitable substituents are as stated for R2 l in Formula IIg.
  • [0064]
    R2 l can also be a monovalent radical of Formula IIIl,
  • [0065]
    wherein Wl is an oxygen or sulfur atom or an N—R6 l group. R5 l is a monovalent radical, such as a hydrogen atom, a C1-C4-alkyl or C3-C7-cycloalkyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R2 l from Formula IIg. R6 l is a monovalent radical, preferably a hydrogen atom, a C1-C4-alkyl group or a C3-C7-cycloalkyl group, a C1-C18-alkanoyl group, a benzoyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R2 l in Formula IIg,
  • [0066]
    R2 l can alternately be a substituent of Formula IVl,
  • [0067]
    where bl is an integer, preferably 2, 3 or 4. Zl is a monovalent radical, such as a formyl, aminocarbonyl or hydrazinocarbonyl group, or a cyclic or acyclic acetal or thioacetal group.
  • [0068]
    R2 l can also be a substituent of Formula Vl,
  • [0069]
    in which bl is an integer, preferably 2, 3 or 4. R7 l is a monovalent radical, such as a glycol oligomer of the formula
  • —O(CH2CH2O)dl—CH3,
  • [0070]
    where dl is an integer, preferably in the range from about 2 to about 4 or from about 40 to about 90.
  • [0071]
    R2 l can further be a carbohydrate of Formula VIl,
  • [0072]
    where R8 l is a monovalent radical, such as a hydrogen atom, a C1-C4-alkanoyl or alkyl group, a benzoyl group or a benzyl group.
  • [0073]
    In another embodiment, G is an β-hydroxy amine of Formula IIIg,
  • [0074]
    where R9 l is a monovalent radical such as a hydrogen atom, a C1-C6-alkyl group or a substituted or unsubstituted aryl group, with aryl and its preferred substituents having the meaning stated for R2 l in Formula IIg. R10 l is a monovalent radical, preferably a hydrogen atom, alkyl, for example, methyl, or a phenyl group.
  • [0075]
    Another subclass of compounds of this invention includes peptides of Formula I wherein G is a hydrazido group of Formula IVg,
  • [0076]
    where R11 l and R12 l are each, independently, a monovalent radical such as a hydrogen atom, a normal or branched C1-C8-alkyl group, a C3-C8- cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group or a substituted or unsubstituted aryl, heteroaryl, aryl-C1-C4-alkyl or heteroaryl-C1-C4-alkyl group, where aryl, heteroaryl and their preferred substituents can be selected from among the options listed for R2 1 in Formula IIg. R11 l and R12 l can also together form a propylene or butylene bridge.
  • [0077]
    Another subclass of compounds of this invention includes peptides of Formula I wherein G is a monovalent radical of the formula —O—R13 l or —S—R13 l, where R13 l is a monovalent radical, such as a C3-C10-cycloalkyl group, a normal or branched C2-C16-alkenylmethyl group or a C1-C16-alkyl group which can be substituted by from 1 to about 5 halogen, preferably fluorine, atoms.
  • [0078]
    R13 l can also be the radical —(CH2)el—R14 l where el is an integer, preferably 1, 2 or 3. R14 l is a monovalent radical, preferably a saturated or partially unsaturated C3-C10-carbocycle.
  • [0079]
    R13 l can further be the radical
  • —[CH2—CH═C(CH3)—CH2]fl—H,
  • [0080]
    where fl is an integer, preferably 1, 2, 3 or 4.
  • [0081]
    R13 l can also be the radical
  • —[CH2—CH2—O]gl—CH3,
  • [0082]
    where gl is an integer, preferably from about 2 to about 4, or from about 40 to about 90.
  • [0083]
    R13 l can also be the radical
  • —(CH2)hl-aryl or —(CH2)hl-heteroaryl,
  • [0084]
    where aryl and heteroaryl can also be substituted and, along with their preferred substituents, can be selected from the group listed for R2 l in Formula IIg. hl is an integer, preferably 0, 1, 2 or 3.
  • [0085]
    R13 l can further be the radical
  • —(CH2)bl-Wl-R5 l,
  • [0086]
    where bl, Wl and R5 l are each selected from among the options described for Formula IIIl.
  • [0087]
    Another subclass of compounds of this invention includes peptides of Formula I in which G is an aminoxy group of the formula
  • —O—N(R15 l)(R16 l),
  • [0088]
    where R15 l and R16 l are each a monovalent radical, and can independently be a hydrogen atom, a normal or branched C1-C8-alkyl group, which can be substituted by halogen, preferably fluorine, atoms, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl or heteroaryl group or a substituted or unsubstituted aryl-C1-C4-alkyl group. Aryl and heteroaryl groups and the preferred substituents thereof can be selected from the options listed for R2 l in Formula IIg. Additionally, R15 l and R16 l can together form a 5-, 6- or 7-membered heterocycle.
  • [0089]
    Another subclass of compounds of this invention includes peptides of Formula I wherein G is an oximato group of the formula
  • —O—N═C(R15 l)(R16 l),
  • [0090]
    where R15 l and R16 l are selected from among the options listed above and, additionally, can together form a cyclic system comprising, preferably, from about 3 to about 7 ring atoms. This cyclic system can additionally be fused to one or more aromatic rings. Particularly preferred cyclic systems are shown below.
  • [0091]
    A further subclass of compounds of this invention includes peptides of Formula I wherein G is a hydrogen atom, a normal or branched C1-C8-alkyl group, which can be substituted by up to six halogen, preferably fluorine, atoms, a C3-C8-cycloalkyl group or a C3-C8-cycloalkyl-C 1-C4-alkyl group.
  • [0092]
    G can also be an arylalkyl, heteroarylalkyl, aryl or heteroaryl group of Formula Vg,
  • —(CH2)ag—R17 l  (Vg)
  • [0093]
    where ag is an integer, such as 0, 1 or 2. R17 l is a substituted or unsubstituted aryl or heteroaryl group. Preferred aryl groups include phenyl and naphthyl groups. Suitable aryl substituents include halogen, preferably fluorine, bromine or chlorine, atoms, C1-C4-alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group, a nitro or cyano group, a C1-C7-alkoxycarbonyl group, a C1-C7- alkylsulfonyl group, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle. R17 l can also be a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system which can be fused to a benzene ring. Suitable heteroaryl groups include imidazolyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, oxazolyl, pyrazolyl, 1,2,4- or 1,2,3-triazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzopyranyl, indolyl, isoindolyl, indazolyl and quinolinyl groups. Preferred heteroaryl substituents are C1-C6-alkyl groups, a hydroxyl group or a phenyl group.
  • [0094]
    Another subclass of compounds of this invention includes compounds of Formula I wherein G is a monovalent radical of Formula VIg,
  • —(CH2)bg—(C═O)cg—OR18 l  (VIg),
  • [0095]
    where bg is an integer, preferably 0, 1, 2 or 3, and cg is an integer, preferably 0 or 1. bg and cg are not both simultaneously 0. R18 l is a monovalent radical, such as a hydrogen atom, a straight-chain or branched C1-C8-alkyl group which can be substituted by halogen, preferably fluorine, atoms, especially a CF2-moiety, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl, group. Suitable aryl substituents are halogen, preferably fluorine, bromine or chlorine, atoms, C1-C4-alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C1-C7-alkoxycarbonyl moiety, a C1-C7-alkylsulfonyl moiety, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
  • [0096]
    G can also be a monovalent radical of Formula VIIg
  • [0097]
    where dg is an integer, preferably 0, 1, 2 or 3, and eg is an integer such as 0 or 1. dg and eg cannot both simultaneously take the value 0. R19 l and R20 l are each, independently, a monovalent radical, such as a hydrogen atom, a straight-chain or branched C1-C8-alkyl group, which can further be substituted by halogen, preferably fluorine, atoms, especially a CF2-moiety, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl group. Suitable aryl substituents include one or more halogen, referably fluorine, bromine or chlorine, atoms, C1-C4-alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C1-C7-alkoxycarbonyl moiety, a C1-C 7-alkylsulfonyl group, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle. N(R19 l)R20 l can additionally form a ring system of the formula N(CH2)fg, where fg is an integer selected from among 4, 5 or 6.
  • [0098]
    Another subclass of compounds of this invention includes peptides of Formula I, wherein G is a monovalent radical of Formula VIIIg,
  • —(CH2)gg—S(O)hg—R21 l  (VIIIg),
  • [0099]
    where gg is an integer, for example, 1 or 2, and hg is 1 or 2. R21 l is a monovalent radical, preferably a methyl group, a trifluoromethyl group, an ethyl group or a phenyl group.
  • [0100]
    G can also be an alkyl- or arylcarbonylalkyl group of Formula IXg,
  • —(CH2)ig—(C═O)—R22 l  (IXg),
  • [0101]
    where R22 l is a monovalent radical, such as a hydrogen atom, a straight-chain or branched C1-C8-alkyl group which can be substituted by up to six halogen, preferably fluorine, atoms, especially a CF2-moiety, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl, group. Suitable aryl substituents are halogen, preferably fluorine, bromine or chlorine, atoms, C1-C4-alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C1-C7-alkoxycarbonyl moiety, a C1-C7-alkylsulfonyl moiety, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
  • [0102]
    Synthetic Methods
  • [0103]
    The compounds of the present invention can be prepared by known methods of peptide synthesis. Thus, the peptides can be assembled sequentially from individual amino acids or by linking suitable small peptide fragments. In sequential assemblage, the peptide chain is extended stepwise, starting at the C-terminus, by one amino acid per step. In fragment coupling, fragments of different lengths can be linked together, and the fragments in turn can be obtained by sequential assembly from amino acids or by fragment coupling of still shorter peptides.
  • [0104]
    In both sequential assemblage and fragment coupling it is necessary to link the units by forming an amide linkage, which can be accomplished via a variety of enzymatic and chemical methods. Chemical methods for forming the amide linkage are described in detail in standard references on peptide chemistry, including Müller, Methoden der organischen Chemie Vol. XV/2, pages 1-364, Thieme Verlag, Stuttgart, Germany (1974); Stewart and Young, Solid Phase Peptide Synthesis, pages 31-34 and 71-82, Pierce Chemical Company, Rockford, Ill. (1984); Bodanszky et al., Peptide Synthesis, pages 85-128, John Wiley & Sons, New York, (1976). Preferred methods include the azide method, the symmetric and mixed anhydride method, the use of in situ generated or preformed active esters, the use of urethane protected N-carboxy anhydrides of amino acids and the formation of the amide linkage using coupling reagents, such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloyl chloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propane-phosphonic anhydride (PPA), N,N-bis(2-oxo-oxazolidinyl)imido-phosphoryl chloride (BOP-Cl), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop), diphenyl-phosphoryl azide (DPPA), Castro's reagent (BOP, PyBop), O-benzotriazolyl-N,N,N′, N′-tetramethyluronium salts (HBTU), diethylphosphoryl cyanide (DEPCN), 2,5-diphenyl-2,3-dihydro-3-oxo-4-hydroxy-thiophene dioxide (Steglich's reagent; HOTDO), and 1,1′-carbonyl-diimidazole (CDI). The coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.
  • [0105]
    Although the use of protecting groups is generally not necessary in enzymatic peptide synthesis, reversible protection of reactive groups not involved in formation of the amide linkage is necessary for both reactants in chemical synthesis. Three conventional protective group techniques are preferred for chemical peptide synthesis: the benzyloxycarbonyl (Z), the t-butoxycarbonyl (Boc) and the 9-fluorenylmethoxycarbonyl (Fmoc) techniques. Identified in each case is the protective group on the α-amino group of the chain-extending unit. A detailed review of amino-acid protective groups is given by Müller, Methoden der organischen Chemie Vol. XV/1, pp 20-906, Thieme Verlag, Stuttgart (1974). The units employed for assembling the peptide chain can be reacted in solution, in suspension or by a method similar to that described by Merrifield (J. Am. Chem. Soc. 85: 2149 (1963)). Particularly preferred methods are those in which peptides are assembled sequentially or by fragment coupling using the Z, Boc or Fmoc protective group technique, with one of the reactants in the said Merrifield technique being bonded to an insoluble polymeric support (also called resin hereinafter). This typically entails assembling the peptide sequentially on the polymeric support using the Boc or Fmoc protective group technique, with the growing peptide chain covalently bonded at the C terminus to the insoluble resin particles. This procedure allows the removal of reagents and byproducts by filtration, eliminating the need to recrystallize intermediates.
  • [0106]
    The protected amino acids can be linked to any suitable polymer, which must be insoluble in the solvents used and have a stable physical form which permits filtration. The polymer must contain a functional group to which the first protected amino acid can be covalently attached. A wide variety of polymers are suitable for this purpose, including cellulose, polyvinyl alcohol, polymethacrylate, sulfonated polystyrene, chloromethylated styrene/divinylbenzene copolymer (Merrifield resin), 4-methylbenzhydrylamine resin (MBHA-resin), phenylacetamidomethyl resin (Pam-resin), p-benzyloxy-benzyl-alcohol-resin, benzhydryl-amine-resin (BHA-resin), 4-(hydroxymethyl)-benzoyl-oxymethyl-resin, the resin of Breipohl et al. (Tetrahedron Letters 28 (1987) 565; supplied by BACHEM), 4-(2,4-dimethoxyphenylaminomethyl) phenoxy resin (supplied by Novabiochem) or o-chlorotrityl-resin (supplied by Biohellas).
  • [0107]
    Solvents suitable for peptide synthesis include any solvent which is inert under the reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of these solvents.
  • [0108]
    Peptide synthesis on the polymeric support can be carried out in a suitable inert organic solvent in which the amino acid derivatives starting materials are soluble. However, preferred solvents additionally have resin-swelling properties and include DMF, DCM, NMP, acetonitrile, DMSO, and mixtures of these solvents. Following synthesis, the peptide is removed from the polymeric support. The conditions under which this cleavage is accomplished for various resin types are disclosed in the literature. The cleavage reactions most commonly used are acid- or palladium-catalyzed, the former being conducted in, for example, liquid anhydrous hydrogen fluoride, anhydrous trifluoromethanesulfonic acid, dilute or concentrated trifluoroacetic acid, and acetic acid/dichloromethane/trifluoroethanol mixtures. The latter can be carried out in THF or THF-DCM-mixtures in the presence of a weak base such as morpholine. Certain protecting groups are also cleaved off under these conditions.
  • [0109]
    Partial deprotection of the peptide may also be necessary prior to certain derivatization reactions. For example, peptides dialkylated at the N-terminus can be prepared either by coupling the appropriate N,N-di-alkylamino acid to the peptide in solution or on the polymeric support or by reductive alkylation of the resin-bound peptide in DMF/1% acetic acid with NaCNBH3 and the appropriate aldehyde.
  • [0110]
    The two schemes which follow present a more detailed description of the synthesis of the compounds of the present invention.
  • [0111]
    The tetrapeptide A-B-D-E-OH is coupled with an amino-derivative F-G to give the final compound A-B-D-E-F-G using the methods for peptide coupling as described above.
  • [0112]
    Here, the N-terminal protected tetrapeptide A′-B-D-E-OH is coupled with an amino-derivative F-G to give an intermediate compound A′-B-D-E-F-G using the methods for peptide coupling as described above. Then, the N-protecting group is removed by conventional methods as described above. The groups RA and R7 A can then be attached to the amino terminus via reductive alkylation as described above.
  • [0113]
    Building blocks of use in the synthesis of the claimed compounds (described in scheme I and II as F-G) can be prepared by the following general methods:
  • [0114]
    a) Synthesis of Amino-phenyl-ketones
  • [0115]
    The following schemes describe synthetic routes to aminophenyl-ketones which are not commercially available.
  • [0116]
    In scheme III.1, the synthesis starts with a nitrobenzaldehyde. Addition of organometallic compounds such as lithium or Grignard reagents led to the corresponding alcohols (Fürstner et al. Tetrahedron 52: 7329-7344 (1996); Fürstner et al., Tetrahedron 51, 773-786 (1995)). These alcohols can be oxidised to the ketones with known oxidation agents, such as chromium(VI) compounds (for example, pyridinium dichromate in dichloromethane, as described by Fürstner et al., supra) or the Dess Martin reagent. The nitrophenyl ketones are then reduced to the corresponding amino-phenyl-ketones either by hydrogenation in presence of a palladium catalyst, such as palladium on carbon, or by metal salts in presence of acids such as the combination of tin(II)chloride and hydrochloric acid (Nunn et al., J. Chem. Soc. 1952: 583-588).
  • [0117]
    A more direct route (see scheme III.2) is the reaction of nitrobenzoyl chlorides with an organometallic reagent such as a lithium or Grignard reagent (Fürstner et al., Tetrahedron 51, 773-786 (1995)).
  • [0118]
    2-Amino-phenyl ketones can be obtained by reaction of the corresponding 2-fluorophenyl-ketone with sodium azide in a polar solvent, such as N,N-dimethylformamide, and subsequent reduction of the intermediate benzisoxazole (see scheme III.3). For example, the synthesis of 2-aminophenyl-(4-pyridazinyl)-ketone has been described by N. Haider et al. (Arch. Pharm. 325: 119-122 (1992)).
  • [0119]
    b) Synthesis of Amino-benzamides
  • [0120]
    The following schemes describe synthetic routes to aminobenzamides which are not commercially available.
  • [0121]
    In scheme IV.1, the steps are described starting from nitrobenzoic acids or substituted nitrobenzoic acids. These acids are coupled with primary or secondary amines (HNR1R2) by using coupling reagents. Preferred method is the use of coupling reagents such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloylchloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propane-phosphonic anhydride (PPA), N,N-bis(2-oxo-3oxazolidinyl)-imidophosphoryl chloride (BOP-Cl), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop), diphenylphosphoryl azide (DPPA), Castro's reagent (BOP, PyBop), O-benzotriazolyl-N,N,N′,N′-tetramethyluronium salts (HBTU), diethylphosphoryl cyanide (DEPCN), 2,5-diphenyl 2,3-dihydro-3-oxo-4-hydroxythiophene dioxide (Steglich's reagent; HOTDO) and 1,1′-carbonyldiimidazole (CDI). The coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), azabenzotriazole, N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.
  • [0122]
    In place of the acids, the corresponding nitro-benzoyl chloride can be used. These are either commercially available or could be synthesized from the corresponding acids with thionyl chloride. The amines react with the nitrobenzoylchlorides in the presence of a base such as pyridine, which can also be used as the solvent (N. S. Cho et al., J. Heterocycl. Chem. 33, 1201-1206 (1996)). The nitro-benzamides are then reduced to the corresponding amino-benzamides by reducing agents such as metal salts in presence of hydrochloride acids or by metal-catalysed hydrogenation using palladium on a solid such as palladium on charcoal as catalyst. This route is described in Example 1.
  • [0123]
    Another method involves transforming the amine to the trifluoroacetamide by treatment with trifluoroacetic anhydride. The amide is deprotonated with a base such as sodium hydride or potassium t-butanolate and then treated with the corresponding alkyl halide such as methyl iodide, ethyl iodide or isopropyl iodide. The trifluoroacetamide is easily cleaved in basic alcoholic solution such as potassium carbonate in methanol.
  • [0124]
    In scheme IV.2. the starting materials for the synthesis of amino-benzamides are the N-protected aminobenzoic acids. Different protecting groups for the nitrogen are compatible such as the above mentioned Z-, Boc- or Fmoc-protecting groups. The N-protected amino-benzoic acids are coupled with amines as described above for the nitro-benzoic acids using the above mentioned coupling conditions. This route is exemplified in Example 2.
  • [0125]
    A route for the preparation of 2-aminobenzamides is described in scheme IV.3. Opening of isatoic anhydride (substituted or unsubstituted at the nitrogen) by amines with evolution of carbon dioxide led to the corresponding 2-amino-benzamides, as described by Clark et al., J. Org. Chem. 9: 55-64 (1944).
  • [0126]
    c) Amino-cyclopentane- or Aminocyclohexane-carboxamides
  • [0127]
    Different routes have been described to the synthesis of cis-2-amino-cyclopentylcarboxylic acid (cispentacin) in racemic form or as pure enantiomer. Using an intramolecular nitrone-olefin cycloaddition cis-2-(t-butoxycarbonylamino)cyclopentane-1-carboxylic acid could be prepared in a few synthetic steps (Konosu et al., Chem. Pharm. Bull. 41: 1012 (1993)). Another route to enantiomerically pure cis-(1R, 2S)-2-amino-cyclopentylcarboxylic acid is the addition of chiral lithium (S)-(-methylbenzyl)benzylamide to t-butyl-1-cyclopentene-1-carboxylate with subsequent removal of the benzyl groups by hydogenation and removal of the t-butyl group by acid treatment (Davies et al., Synlett 1993, p. 461). The corresponding trans-epimer could be obtained by isomerisation with a base such as potassium t-butoxide. By using the lithium (R)-(-methylbenzyl)benzylamide in the Michael addition (1S, 2R)-2-amino-cyclopentylcarboxylic acid and (1S, 2S)-2-amino-cyclopentylcarboxylic acid can be obtained. This method is also applicable to the synthesis of cis-and trans-aminocyclohexane-1-carboxylic acid.
  • [0128]
    Resolution of racemic Boc-protected cis-2-aminocyclopentane carboxylic acid (Bernath et al., Acta Chim. 74: 479 (1972); Nativ et al., Isr. J. Chem. 10: 55 (1972)) can be achieved with (+)- and (−)-ephedrine in high enantiomeric excess (Nöteberg et al., Tetrahedron 53: 7975 (1997)). In this paper also the synthesis of the trans-enantiomers of Boc-protected trans-2-aminocyclopentane carboxylic methyl ester was described, starting with either trans-(3R, 4R)-bis(methoxycarbonyl)cyclopentanone or trans(3S,4S)-bis(methoxycarbonyl)-cyclopentanone.
  • [0129]
    Amides of Boc-protected 2-aminocyclopentylcarboxylic acid can be obtained by coupling the acid with the corresponding amine using the standard procedures as described above for the coupling of nitrobenzoic acid with amines or as described in D. Nöteberg et al., Tetrahedron 53: 7975 (1997). Deprotection of the amine function can be achieved by using Lewis acids, for example, a mineral acid such as hydrochloric acid in ether or dioxane or an organic acid, such as trifluoroacetic acid in methylene chloride.
  • [0130]
    Methods of Use of the Claimed Compounds
  • [0131]
    In another embodiment, the present invention comprises a method for partially or totally inhibiting formation of, or otherwise treating (e.g., reversing or inhibiting the further development of) solid tumors (e.g., tumors of the lung, breast, colon, prostate, bladder, rectum, or endometrial tumors) or hematological malignancies (e.g., leukemias, lymphomas) in a mammal, for example, a human, by administering to the mammal a therapeutically effective amount of a compound or a combination of compounds of Formula I. The agent may be administered alone or in a pharmaceutical composition comprising the agent and an acceptable carrier or diluent. Administration may be by any of the means which are conventional for pharmaceutical, preferably oncological, agents, including oral and parenteral means such as subcutaneously, intravenously, intramuscularly and intraperitoneally, nasally or rectally. The compounds may be administered alone or in the form of pharmaceutical compositions containing a compound of Formula I together with a pharmaceutically accepted carrier appropriate for the desired route of administration. Such pharmaceutical compositions may be combination products, i.e., they may also contain other therapeutically active ingredients.
  • [0132]
    The dosage to be administered to the mammal, such as a human, will contain a therapeutically effective amount of a compound described herein. As used herein, “therapeutically effective amount” is an amount sufficient to inhibit (partially or totally) formation of a tumor or a hematological malignancy or to reverse development of a solid tumor or other malignancy or prevent or reduce its further progression. For a particular condition or method of treatment, the dosage is determined empirically, using known methods, and will depend upon factors such as the biological activity of the particular compound employed; the means of administration; the age, health and body weight of the recipient; the nature and extent of the symptoms; the frequency of treatment; the administration of other therapies; and the effect desired. A typical daily dose will be from about 5 to about 250 milligrams per kilogram of body weight by oral administration and from about 1 to about 100 milligrams per kilogram of body weight by parenteral administration.
  • [0133]
    The compounds of the present invention can be administered in conventional solid or liquid pharmaceutical administration forms, for example, uncoated or (film-)coated tablets, capsules, powders, granules, suppositories or solutions. These are produced in a conventional manner. The active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, sustained release compositions, antioxidants and/or propellant gases (cf. H. Sücker et al.: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). The administration forms obtained in this way typically contain from about 1 to about 90% by weight of the active substance.
  • [0134]
    The following examples are intended to illustrate the invention but are not to be considered limitations of the invention.
  • EXAMPLES
  • [0135]
    The proteinogenous amino acids are abbreviated in the examples using the known three-letter code. Other abbreviations employed are: TFA=trifluoroacetic acid, Ac= acetic acid, DCM=dichloromethane, DMSO= dimethylsulfoxide, Bu=butyl, Et=ethyl, Me=methyl, Bn= benzyl. In the compounds listed, all proteinogenous amino acids are L-amino acids unless otherwise noted.
  • [0136]
    General Materials and Methods
  • [0137]
    The compounds of the present invention are synthesized by classical solution synthesis using standard Z- and Boc-methodology as discussed above or by standard methods of solid-phase synthesis on a model 431A synthesizer supplied by APPLIED BIOSYSTEMS. This apparatus uses different synthetic cycles for the Boc and Fmoc protective group techniques, as described below.
    Synthetic cycle for the Boc protecting group technique
    1. 30% trifluoroacetic acid in DCM 1 × 3 min
    2. 50% trifluoroacetic acid in DCM 1 × 1 min
    3. DCM washing 5 × 1 min
    4. 5% diisopropylethylamine in DCM 1 × 1 min
    5. 5% diisopropylethylamine in NMP 1 × 1 min
    6. NMP washing 5 × 1 min
    7. Addition of preactivated  1 × 30 min
    protected amino acid
    (activation with 1 equivalent of
    DCC and 1 equivalent of HOBt in
    NMP/DCM);
    Peptide coupling (1st part)
    8. Addition of DMSO to the reaction
    mixture until it contains 20% DMSO
    by volume
    9. Peptide coupling (2nd part)  1 × 16 min
    10. Addition of 3.8 equivalents of
    diisopropylethylamine to the reaction
    mixture
    11. Peptide coupling (3rd part) 1 × 7 min
    12. DCM washing 3 × 1 min
    13. if conversion is incomplete,
    repetition of coupling (back to step 5)
    14. 10% acetic anhydride,
    5% diisopropylethylamine in DCM 1 × 2 min
    15. 10% acetic anhydride in DCM 1 × 4 min
    16. DCM washing 4 × 1 min
    17. back to step 1.
  • [0138]
    BOP-Cl and PyBrop were used as reagents for coupling an amino acid to an N-methylamino acid. The reaction times were correspondingly increased. In solution synthesis, the use of either Boc-protected amino acid NCAs (N-tert-butyloxycarbonyl-amino acid-N-carboxy-anhydrides) or Z-protected amino acid NCAs (N-benzyloxycarbonyl-amino acid-N-carboxy-anhydrides) respectively is most preferable for this type of coupling.
    Synthetic cycle for the Fmoc protective group technique
    1. DMF washing 1 × 1 min
    2. 20% piperidine in DMF 1 × 4 min
    3. 20% piperidine in DMF  1 × 16 min
    4. DMF washing 5 × 1 min
    5. Addition of the preactivated  1 × 61 min
    protected amino acid (activation
    by 1 equivalent of TBTU and
    1.5 equivalent of DIPEA in DMF);
    Peptide coupling
    6. DMF washing 3 × 1 min
    7. If conversion is incomplete,
    repetition of coupling (back to 5.)
    8. 10% acetic anhydride in DMF 1 × 8 min
    9. DMF washing 3 × 1 min
    10. back to 2.
  • [0139]
    BOP-Cl and PyBrop were used as reagents for coupling an amino acid to an N-methylamino acid. The reaction times were correspondingly increased.
  • [0140]
    Reductive Alkylation of the N Terminus
  • [0141]
    The peptide-resin prepared as described above was deprotected at the N terminus and then reacted with a 3-fold molar excess of aldehyde or ketone in DMF/1% acetic acid with addition of 3 equivalents of NaCNBH3. After reaction was complete (negative Kaiser test), the resin was washed several times with water, isopropanol, DMF and dichloromethane.
  • [0142]
    Workup of the Peptide-Resins
  • [0143]
    The peptide-resin obtained via the Boc protecting group technique was dried under reduced pressure and transferred into a reaction vessel of a TEFLON HF apparatus (supplied by PENINSULA). A scavenger, usually anisole (1 mL/g of resin), was then added and additionally, in the case of tryptophan-containing peptides, a thiol (0.5 mL/g of resin), preferably ethanedithiol, to remove the indolic formyl group. This was followed by condensing in hydrogen fluoride (10 mL/g of resin) in a bath of liquid N2. The mixture was allowed to warm to 0° C. and stirred at this temperature for 45 min. The hydrogen fluoride was then stripped off under reduced pressure, and the residue was washed with ethyl acetate to remove any remaining scavenger. The peptide was extracted with 30% acetic acid and filtered, and the filtrate was lyophilized.
  • [0144]
    The peptide-resin formed by the Fmoc protecting group method was dried under reduced pressure and then subjected to one of the following cleavage procedures, depending upon the amino-acid composition (Wade, Tregear, Howard Florey Fmoc Workshop Manual, Melbourne 1985). The suspension of the peptide-resin in the suitable TFA mixture was stirred at room temperature for the stated time and then the resin was filtered off and washed with TFA and DCM. The filtrate and the washings were concentrated, and the peptide was precipitated by addition of diethyl ether. After cooling in an ice bath, the precipitate was filtered off, taken up in 30% acetic acid and lyophilized.
  • [0145]
    When an o-chlorotrityl-resin (supplied by Biohellas) was used, the suspension of the peptide-resin in an acetic acid/trifluoroethanol/dichloromethane mixture (1:1:3) was stirred at room temperature for 1 h. The suspension was then filtered with suction and the peptide-resin was thoroughly washed with the cleavage solution. The combined filtrates were concentrated in vacuo and treated with water. The precipitated solid was removed by filtration or centrifugation, washed with diethyl ether and dried under reduced pressure.
  • [0146]
    Purification and Characterization of the Peptides
  • [0147]
    Purification was carried out by gel chromatography (SEPHADEX G-10, G-15/10% HOAc, SEPHADEX LH20/MeOH) with or without subsequent medium pressure chromatography (stationary phase: HD-SIL C-18, 20-45 m, 100 Å; mobile phase: gradient with A=0.1% TFA/MeOH, B=0.1% TFA/H2O). The purity of the resulting products was determined by analytical HPLC (stationary phase: 100 2.1 mm VYDAC C-18, 5 l, 300 Å; mobile phase: CH3CN/H2O gradient, buffered with 0.1% TFA, 40%C).
  • [0148]
    The polypeptides were characterized by amino-acid analysis and fast atom bombardment mass spectroscopy.
  • EXAMPLE 1 Synthesis of (2)-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)2 (Compound I-78)
  • [0149]
    Me2Val-Val-MeVal-Pro-OH and Z-Val-Val-MeVal-Pro-OH were prepared by the method disclosed in patent applications DE 4415998 and DE 19527575, the contents of which are incorporated herein by reference.
  • [0150]
    a) Synthesis of N,N-dimethyl-2-nitrobenzamide
  • [0151]
    To a solution of 2.0 g 2-nitrobenzoic acid and 0.98 g dimethylammonium chloride in dichloromethane at 0° C. were added 2.29 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1.62 g N-hydroxy-benzotriazol and 6.05 g N-methyl-morpholine. The resulting mixture was stirred at room temperature overnight. The reaction mixture was then washed sequentially with saturated sodium hydrogen carbonate, a 5% aqueous solution of citric acid and brine. The organic phase was dried over sodium sulfate. After filteration the solvent was removed in vacuo yielding N,N-dimethyl-2-nitrobenzamide (2.13 g).
  • [0152]
    [0152]1H-NMR (DMSO, 270 MHz) d=2.7 (s, 3H), 3.0 (s, 3H), 7.5 (d, 1H), 7.7 (dd, 1H), 7.85 (dd, 1H), 8.15 (d, 1H) ppm
  • [0153]
    b) Synthesis of N,N-dimethyl-2-aminobenzamide
  • [0154]
    Palladium on charcoal (0.54 g, 10% Pd by weight) was added to a solution of 2.1 g N,N-dimethyl-2-nitrobenzamide in 150 mL methanol. The resulting suspension was hydrogenated at room temperature at atmospheric pressure for three hours. After filtration of the catalyst, the solvent was removed in vacuo affording N,N-dimethyl-2-aminobenzamide (1.8 g).
  • [0155]
    [0155]1H-NMR (DMSO, 270 MHz) d=2.9 (s, 6H), 5.1 (s, 2H), 6.5 (dd, 1H), 6.65 (d, 1H), 7.95 (d, 1H), 7.0 (dd, 1H) ppm
  • [0156]
    c) Synthesis of (2)-(Z-Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)2
  • [0157]
    To a solution of 2.0 g Z-Val-Val-MeVal-Pro-OH and 0.53 g N,N-dimethyl-2-amino-benzamide in dichloromethane was added 1.66 g bromo-tris-pyrrolidinophosphonium hexafluoro-phosphate (PyBrop) and 0.77 g N-ethyldiisopropylamine at 0° C. The mixture was stirred at room temperature overnight, and then washed sequentially with saturated sodium hydrogen carbonate, a 5% aqueous solution of citric acid, and brine. The organic phase was dried over sodium sulfate. After filtration, the solvent was removed in vacuo. The residue was purified by silica gel chromatography (1:3 dichloromethane:ethyl acetate) to provide (2)-(Z-Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)2 (1.8 g).
  • [0158]
    FAB-MS 707.0 (M+H+d)
  • [0159]
    d) Synthesis of 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)2
  • [0160]
    Palladium on charcoal (58 mg, 10% Pd by weight) was added to a solution of 1.8 g 2-(Z-Val-Val-MeVal-Pro-NH)—C 6H4—CON(CH3)2 in 150 mL methanol. The resulting suspension was hydrogenated at room temperature at atmospheric pressure for three hours, then 1.5 mL of an aqueous formaldehyde solution (37% formaldehyde by weight) and 341 mg of palladium on charcoal were added. The mixture was hydrogenated at room temperature at atmospheric pressure overnight. After filtration over celite the solvent was removed in vacuo to give 1.30 g 2-(Me2Val-Val-MeVal-Pro-NH)—C 6H4—CON(CH3)2.
  • [0161]
    FAB-MS: 601.0 (M+H+)
  • [0162]
    [0162]1H-NMR (DMSO, 270 MHz) d=0.7 (s, 6H), 0.8-1.0 (m, 12H), 1.75 (m, 1H), 1.8- 2.2 (m, 6H), 2.2 (s, 6H), 2.6 (d, 1H), 2.8 (s, 3H), 2.9 (s, 3H), 3.05 (s, 3H), 3.55, 3.7 (m, 2H), 4.4 (m, 1H), 4.5 (m, 1H), 5.0 (d, 1H), 7.2 (dd, 1H), 7.25 (d, 1H), 7.4, dd, 1H), 7.6 (dd, 1H), 8.0 (d, 1H), 9.6 (s, 1H)
  • EXAMPLE 2 Synthesis of (2)-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)(OCH3) (Compound I-60)
  • [0163]
    a) Synthesis of N,O-dimethyl-(2-N-tert.butoxycarbonyl-amino)benzohydroxylamide
  • [0164]
    To a solution of 1.5 g 2-N-t-butoxy-carbonyl anthranilic acid and 0.68 g N,O-dimethylhydroxylamine hydrochloride in dichloromethane at 0° C., 1.33 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 0.94 g N-hydroxybenzotriazol and 3.20 g N-methylmorpholine were added. The mixture was stirred at room temperature overnight. The reaction mixture was washed sequentially with saturated aqueous sodium hydrogen carbonate, a 5% aqueous solution of citric acid and brine. The organic phase was dried over sodium sulfate. After filtration the solvent was removed in vacuo. Flash chromatography (silica gel, heptane:ethyl acetate 10:1) afforded N,O-dimethyl-(2-N-tert.Butoxycarbonyl-amino)benzohydroxylamide (1.18 g).
  • [0165]
    [0165]1H-NMR (CDCl3, 270 MHz) d=1.5 (s, 9H), 3.4 (s, 3H), 3.6 (s, 3H), 7.0 (dd, 1H), 7.2-7.4 (m, 2H), 8.1 (d, 1H), 8.4 (s, 1H)
  • [0166]
    b) Synthesis of N,O-dimethyl-(2-amino)benzohydroxylamide hydrochloride.
  • [0167]
    To a solution of 0.5 g N,O-dimethyl-(2-N-tert.butoxycarbonyl-amino)benzohydroxylamide in 15 mL dichloromethane at 0° C. was added 17 mL of a hydrogen chloride solution in ether and the resulting solution was stirred for 2 hours. The solvent was evaporated to give 0.41 g N,O-dimethyl-(2-amino)benzohydroxylamide hydrochloride.
  • [0168]
    [0168]1H-NMR (CDCl3, 270 MHz) d=3.4 (s, 3H), 3.6 (s, 3H), 7.3 (dd, 1H) , 7.5 (dd, 2H) , 7.6 (d, 1H), 7.9 (d, 1H)
  • [0169]
    c) Synthesis of (2)-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)(OCH3)
  • [0170]
    To a solution of 0.892 g Me2Val-Val-MeVal-Pro-OH and 0.234 g triethylamine in 10 mL dichloromethane at 0° C. was added 0.218 g formate. After stirring the resulting mixture for two hours, 0.41 g N,O-dimethyl-(2-amino)benzohydroxylamide hydrochloride and 0.234 g triethylamine were added and the mixture was stirred overnight at room temperature. The reaction mixture was washed sequentially with saturated sodium hydrogen carbonate solution and brine. The organic phase was dried over sodium sulfate. After filtration the solvent was removed in vacuo. The residue was purified by chromatography (silica gel treated with 1% triethylamine, solvent: dichloromethane/3% isopropanol) to provide 0.28 g (2)-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)(OCH3).
  • [0171]
    FAB-MS: 617.5 (M+H+)
  • [0172]
    [0172]1H-NMR (DMSO, 270 MHz) d=0.7 (s, 6H), 0.8-1.0 (m, 12H), 1.7 (m, 1H), 1.8-2.2 (m, 6H), 2.2 (s, 6H), 2.6 (d, 1H), 3.0 (s, 3H), 3.2 (s, 3H), 3.5 (s, 3H), 3.5, 3.7 (m, 2H), 4.4 (m, 1H), 4.5 (m, 1H) , 5.0 (d, 1H), 7.2 (dd, 1H), 7.3-7.5 (m, 2H), 7.6 (dd, 1H), 8.0 (d, 1H), 9.65 (s, 1H)
  • EXAMPLE 3 Synthesis of Me2-Val-Val-MeVal-Pro-[cis-2-aminocyclopentanecarboxylic acid]-NHBn (Compound VII-2)
  • [0173]
    d) Synthesis of Racemic Cyclopentane-cis-1,2-dicarboxylic Acid Anhydride
  • [0174]
    8.4 g (44.3 mmol) of commercially available cyclopentane-trans-1,2-dicarboxylic acid was refluxed for 20 h in 75 ml of acetic acid anhydride, then evaporated and the obtained residue distilled in a “Kugelrohr-apparatus” at 1.0 mbar. The fraction boiling at 165° was collected, yielding 5.8 g of the product as an oil.
  • [0175]
    [0175]13C-NMR (400 MHz; DMSO-d6) d (ppm): 25.3 (C-4), 30.6 (C-3,5), 45.7 (C-1,2), 175.6 (C-6,7).
  • [0176]
    b) Synthesis of Racemic Cis-2-carbamoylcyclopentanecarboxylic Acid
  • [0177]
    1.1 g (7.85 mmol) of cyclopentane-cis-1,2-dicarboxylic acid anhydride were added to 8 ml of an aqueous NH3-solution and stirred until dissolution of the educt. The excess of ammonia was then evaporated, the remaining solution cooled to 0° C. and acidified with conc. HCl. The resulting precipitate was filtered off, washed with cold water and dried, yielding 0.7 g of cis-2-carbamoylcyclopentanecarboxylic acid with a melting point of 132-133° C. (lit.: 126-128° C.).
  • [0178]
    c) Synthesis of Racemic Cis-2-aminocyclopentanecarboxylic Acid
  • [0179]
    Under stirring at 0° C. 0.41 g (2.6 mmol) of Br2 were added to an aqueous solution (1.8 mL) of 0.48 g (12 mmol) NaOH. The mixture was cooled again and then 0.34 g (2.16 mmol) of cis-2-carbamoylcyclopentanecarboxylic acid added. After stirring for about 10 minutes again 0.35 g (8.65 mmol) NaOH—dissolved in 1.35 ml of water—were added, and then the whole mixture warmed to 75° C. for about 5 minutes. The mixture then was cooled again, neutralized by addition of conc. HCl, acidified with acetic acid and evaporated to dryness. The residue obtained was extracted five times with refluxing ethanol, and the combined ethanol-fractions evaporated again yielding 1.1 g of a white solid.
  • [0180]
    Purification was achieved by filtration of this residue over a column with Dowex 50 ion exchange resin. Therefore the column was washed with a solution of the solid in water, and then the product eluted by treatment with solid was dissolved in water and the column, absorbed on by washing the column with aqueous diluted NH3. After evaporation of the water the remaining crude product was recristallized from acetone yielding 0.14 g of pure cis-2-aminocyclopentanecarboxylic acid with a melting point of 200-202° C.
  • [0181]
    d) Synthesis of Racemic Cis-2-t-butyloxycarbonylaminocyclopentanecarboxylic Acid Benzylamide
  • [0182]
    To a solution of 1.5 g (11.6 mmol) of cis-2-aminocyclopentanecarboxylic acid in a mixture of acetonitrile/water 3:1 were added 3.3 g (15.1 mmol) of ditbutyldicarbonate, 0.5 g (12.2 mmol) of NaOH dissolved in 12 ml of H2O and 0.1 g (0.82 mmol) of DMAP. The mixture was stirred at ambient temperature for about 3 days, then diluted with water, extracted with ethylacetate. The combined organic phases were washed with a saturated aqueous NaCl-solution, dried over MgSO4 and evaporated to dryness leaving 1.3 g of the Boc-protected compound as an oil. A solution of the crude product and 0.65 g (6.1 mmol) benzylamine in a mixture of THF/DMF 10:1 was cooled to −10° C., then were added subsequently 0.9 g (5.86 mmol) of HOBT, 1.12 g (5.86 mmol) of EDC×HCl and 3 ml of NMM. The mixture was stirred for 2 h at −10° C., for 3 h at 0° C. and was then allowed to warm up to room temperature. After evaporation to dryness the remaining residue was dissolved in ethylacetate, washed with aqueous solutions of 5% citric acid, NaHCO3 and NaCl and dried over MgSO4. Evaporation yielded 1.3 g of cis-2-t-butyloxycarbonylaminocyclo-pentanecarboxylic acid benzylamide as an oil.
  • [0183]
    HPLC (gradient 2): Rt 10.5 min.
  • [0184]
    (Column: Machery & Nagel Nucleosil C18 PPN, 100×2.1, 5 m/100 A, acetonitrile/H2O+0.1% TFA; flow: 0.2 ml/min; temp. 40° C.).
  • [0185]
    [0185]1H-NMR (270 MHz; DMSO-d6) d (ppm): 1.35 (s, 9H), 1.35-1.95 (m, 6H), 2.82 (m, 1H), 4.03 (m, 1H), 4.25 (m, 2H), 6.35 (d, NH), 7.1-7.35 (m, 5H), 8.3 (m, 1H).
  • [0186]
    e) Synthesis of Racemic Cis-2-aminocyclopentanecarboxylic Acid Benzylamide Hydrochloride
  • [0187]
    To a solution of 0.7 g (2.2 mmol) of of cis-2-tert.butyloxycarbonylaminocyclo-pentanecarboxylic acid benzylamide in 30 ml CH2Cl2 were added 25 ml of saturated HCl in diethylether; the mixture was then stirred for 2 h at ambient temperature. Evaporation to dryness and coevaporation with toluene yielded 0.6 g of the deprotected amine as hydrochloride salt.
  • [0188]
    f) Synthesis of Me2-Val-Val-MeVal-Pro-[cis-2-aminocyclopentanecarboxylic Acid]-NHBn (Compound VII-2)
  • [0189]
    To a solution of 0.86 g (1.9 mmol) of the tetrapeptide Me2Val-Val-MeVal-Pro-OH and 0.56 g (2.2 mmol) aminocyclo-pentanecarboxylic acid benzylamide hydrochloride in 30 ml of THF/DMF 5:1 were added subsequently at −10° C. 0.29 g (1.9 mmol) of HOBT; 0.37 g (1.9 mmol) of EDC×HCl and 1.2 ml of NMM. The mixture was stirred for another at −10° C., then for 1-2 h at 0° C. and then allowed to warm up to ambient temperature. After evaporation the remaining residue was diluted with ethyl acetate, washed with an aqueous solution of NaCl, dried over MgSO4 and evaporated again. The remaining crude product (1.2 g) was purified by flash cromatography on silica gel (CH2Cl2/CH3OH) yielding 0.37 g of Me2Val-Val-MeVal-Pro-[cis-2-aminocyclopentanecarboxylic acid]-NHBn.
  • [0190]
    FAB-MS: 655 (M+H+).
  • [0191]
    The following compounds can be prepared as outlined in Schemes I-III and according to the above examples.
  • [0192]
    Table 1:
  • [0193]
    A is Me2Val, B is Val, D is MeVal, E is Pro, F is of Formula IIF and the group —C(═O)-G is in position 2 relative to the nitrogen atom. G is of Formula IIg or, IIIg or IVg.
    No. RF R1 F R2 F —C(═O)—G
    I-1 H H H —NH—CH3
    I-2 H H H —NH—CH2—C6H5
    I-3 H H H —NH-isoC3H5
    I-4 H H H —NH—C6H5
    I-5 H H H 1,3-Thiazol-2-yl-amide
    I-6 H 4-OCH3 5-OCH3 —NH—CH3
    I-7 H 3-cycloC5H9 H —NH—CH3
    I-8 H H H —NH—C2H5
    I-9 H H H —NH-nC3H7
    I-10 H H H —NH-nC4H9
    I-11 H H H —NH-tertC4H9
    I-12 H H H —NH-cycloC3H5
    I-13 H H H —NH-cycloC4H7
    I-14 H H H —NH-cycloC5H9
    I-15 H H H —NH-cycloC6H11
    I-16 H H H —NH-cycloC7H12
    I-17 H H H —NH—CH3—O—CH3
    I-18 H H H —NH—CH2—CH2—O—CH3
    I-19 H H H —NH-1-adamantyl
    I-20 H H H —NH-(4-HO-C6H5)
    I-21 H H H —NH-(2-CF3—C6H4)
    I-22 H H H —NH-(3-CF3—C6H4)
    I-23 H H H —NH-(4-CF3—C6H4)
    I-24 H H H —NH-(2-OCH3—C6H4)
    I-25 H H H —NH-(3-OCH3—C6H4)
    I-26 H H H —NH-(4-OCH3—C6H4)
    I-27 H H H —NH-(2-SCH3—C6H4)
    I-28 H H H —NH-(3-SCH3—C6H4)
    I-29 H H H —NH-(4-SCH3—C6H4)
    I-30 H H H —NH-(2-N(CH3)2—C6H4)
    I-31 H H H —NH-(3-N(CH3)2—C6H4)
    I-32 H H H —NH-(4-N(CH3)2—C6H4)
    I-33 H H H —NH-(4-CN-C6H4)
    I-34 H H H —NH-(4-Cl-C6H4)
    I-35 H H H —NH-(4-Br-C6H4]
    I-36 H H H —NH-(4-F-C6H4]
    I-37 H H H —NH-(4-CH3—C6H4)
    I-33 H H H —NH-(2-NO2—C6H4)
    I-39 H H H —NH-(3-NO2—C6H4)
    I-40 H H H —NH-(4-NO2—C6H4)
    I-41 H H H —NH-(2,4-OCH3—C6H3)
    I-42 H H H —NH-(3,4-OCH3—C6H3)
    I-43 H H H —NH-(3,4,5-OCH3—C6H2)
    I-44 H H H —NH-(3,4-CH2OCH2—C6H3)
    I-45 H H H —NH-(2,3-CH2OCH2—C6H3)
    I-46 H H H —NH-2-pyridinyl
    I-47 H H H —NH-2-furanyl
    I-48 H H H —NH-2-thienyl
    I-49 H H H —NH-3-pyridinyl
    I-50 H H H —NH-3-furanyl
    I-51 H H H —NH-3-thienyl
    I-52 H H H —NH-4-pyridinyl
    I-53 H H H —NH-2-oxazolyl
    I-54 H H H —NH-3-isoxazolyl
    I-55 H H H —NH-4-isoxazolyl
    I-56 H H H —NH-5-isoxazloyl
    I-57 H H H —NH-2R-(but-2-yl)
    I-58 H H H —NH-2S-(but-2-yl)
    I-59 H H H —NH—O—CH3
    I-60 H H H —N(CH3) (OCH3)
    I-61 H H H —N(—(CH2)3—O—)
    I-62 H H H —NH—O—CH2—C6H5
    I-63 H H H —N(CH3)(O—CH2—C6H5)
    I-64 H H H —N(—(CH2)2—CH(C6H5)—O—)
    I-65 H H H —NH—O—C2H5
    I-66 H H H —N(C2H5)(OC2H5)
    I-67 H H H —N(CH2)(OC2H5)
    I-58 H H H —NH—O-isoC3H7
    I-69 H H H —N(CH3)(O-isoC3H7)
    I-70 H H H —NH—O—nC3H7
    I-71 H H H —N(CH3)(O—nC3H7)
    I-72 H H H —NH—O—nC4H9
    I-73 H H H —N(CH2)(O—nC4H9)
    I-74 H H H —NH-O-tertC4H9
    I-75 H H H —N(CH3)(O-tertC4H9)
    I-76 H H H —NH—O—C6H5
    I-77 H H H —N(CH3)(O—C6H5)
    I-78 H H H —N(CH3)2
    I-79 H H H —N(CH2—C6H5)2
    I-80 H H H —N(C2H5)2
    I-81 H H H —N(isoC3H7)2
    I-82 H H H —N(nC3H7)2
    I-83 H H H —N(nC4H9)2
    I-84 H H H —N(C6H5)2
    I-85 H H H —NH—CH2—CH2—OH
    I-86 H H H —NH—(CH2)3—OH
    I-87 H H H —NH(—(CH2)2CH(C6H5)OH)
    I-88 H H H —NH—(CH2)4—OH
    I-89 H H H —NH(—CH(CH3)—CH2—OH)
    I-90 H H H —NH(—CH2—CH(CH3)—OH)
    I-91 H H H —NH(CH(CH3)(CH2)2OH)
    I-92 H H H —NH(—(CH2)2CH(CH3)OH)
    I-93 H 4-CH3 H —NH—CH3
    I-94 H 4-CH3 H —NH—CH2—C6H5
    I-95 H 4-CH3 H —NH—isoC3H7
    I-96 H 4-CH3 H —NH—C6H5
    I-97 H 4-CH3 H —NH—C2H5
    I-98 H 4-CH3 H —NH-nC3H7
    I-99 H 4-CH3 H —NH—nC4H9
    I-100 H 4-CH3 H —NH-tertC4H9
    I-101 H 4-CH3 H —NH-cycloC3H5
    I-102 H 4-CH3 H —NH- cycloC4H7
    I-103 H 4-CH3 H —NH-cycloC5H9
    I-104 H 4-CH3 H —NH-cycloC6H11
    I-105 H 4-CH3 H —NH-1-adamantyl
    I-106 H 4-CH3 H —NH-2R-(but-2-yl)
    I-107 H 4-CH3 H —NH-2S-(but-2-yl)
    I-108 H 4-CH3 H —NH—O—CH3
    I-109 H 4-CH3 H —N(CH3)(OCH3)
    I-110 H 4-CH3 H —N(—(CH3—O—)
    I-111 H 4-CH3 H —N(CH3)2
    I-112 H 4-CH3 H —N(CH2—C6H5)2
    I-113 H 4-CH3 H —N(C2H5)2
    I-114 H 4-CH3 H —N(isoC3H7)2
    I-115 H 4-CH3 H —N(nC3H7)2
    I-116 H 4-CH3 H —N(nC4H9)2
    I-117 H 4-CH3 H —N(C6H5)2
    I-118 H 5-CH3 H —NH—CH3
    I-119 H 5-CH3 H —NH—CH2—C6H5
    I-120 H 5-CH3 H —NH-isoC3H7
    I-121 H 5-CH3 H —NH-C6H5
    I-122 H 5-CH3 H —NH-C2H5
    I-123 H 5-CH3 H —NH-nC3H7
    I-124 H 5-CH3 H —NH-nC4H9
    I-125 H 5-CH3 H —NH-tertC4H9
    I-126 H 5-CH3 H —NH-cycloC3H5
    I-127 H 5-CH3 H —NH-cycloC4H7
    I-128 H 5-CH3 H —NH-cycloC5H9
    I-129 H 5-CH3 H —NH-cycloC6H11
    I-130 H 5-CH3 H —NH-1-adamantyl
    I-131 H 5-CH3 H —NH-2R-(but-2-yl)
    I-132 H 5-CH3 H —NH-2S-(but-2-yl)
    I-133 H 5-CH3 H —NH—O—CH3
    I-134 H 5-CH3 H —N(CH3)(OCH3)
    I-135 H 5-CH3 H —N(—(CH3)3—O—)
    I-136 H 5-CH3 H —N(CH3)2
    I-137 H 5-CH3 H —N(CH2—C6H5)2
    I-138 H 5-CH3 H —N(C2H5)2
    I-139 H 5-CH3 H —N(isoC3H7)2
    I-140 H 5-CH3 H —N(nC3H7)2
    I-141 H 5-CH3 H —N(nC4H9)2
    I-142 H 5-CH3 H —N(C6H5)2
    I-143 CH3 H H —NH—CH3
    I-144 CH3 H H —NH—CH2—C6H5
    I-145 CH3 H H —NH—isoC3H7
    I-146 CH3 H H —NH-C6H5
    I-147 CH3 H H —NH-C2H5
    I-148 CH3 H H —NH-nC3H7
    I-149 CH3 H H —NH-nC4H9
    I-150 CH3 H H —NH-tertC4H9
    I-151 CH3 H H —NH-cycloC3H5
    I-152 CH3 H H —NH-cycloC4H7
    I-153 CH3 H H —NH-cycloC5H9
    I-154 CH3 H H —NH-cycloC6H11
    I-155 CH3 H H —NH-1-adamantyl
    I-156 CH3 H H —NH-2R-(but-2-yl)
    I-157 CH3 H H —NH-2S-(but-2-yl)
    I-158 CH3 H H —NH—O—CH3
    I-159 CH3 H H —N(CH3)(OCH3)
    I-160 CH3 H H —N(—(CH2)3—O—)
    I-161 CH3 H H —N(CH3)2
    I-162 CH3 H H —N(CH2—C6H5)3
    I-163 CH3 H H —N(C2H5)2
    I-164 CH3 H H —N(isoC3H7)2
    I-165 CH3 H H —N(nC3H7)2
    I-155 CH3 H H —N(nC4H9)2
    I-167 CH3 H H —N(C6H5)2
    I-168 H 4-OCH3 H —NH—CH3
    I-159 H 4-OCH3 H —NH—CH2—C6H5
    I-170 H 4-OCH3 H —NH-isoC3H7
    I-171 H 4-OCH3 H —NH-C6H5
    I-172 H 4-OCH3 H —NH-C2H5
    I-173 H 4-OCH3 H —NH-nC4H7
    I-174 H 4-OCH3 H —NH-nC5H9
    I-175 H 4-OCH3 H —NH-tertC4H9
    I-176 H 4-OCH3 H —NH-cycloC3H5
    I-177 H 4-OCH3 H —NH-cycloC4H7
    I-178 H 4-OCH3 H —NH-cycloC5H9
    I-179 H 4-OCH3 H —NH-cycloC6H11
    I-180 H 4-OCH3 H —NH-1-adamantyl
    I-181 H 4-OCH3 H —NH-2R-(but-2-yl)
    I-182 H 4-OCH3 H —NH-2S-(but-2-yl)
    I-183 H 4-OCH3 H —NH—O—CH3
    I-184 H 4-OCH3 H —N(CH3)(OCH3)
    I-185 H 4-OCH3 H —N(—(CH2)3—O—)
    I-186 H 4-OCH3 H —N(CH3)2
    I-187 H 4-OCH3 H —N(CH2—C6H5)2
    I-188 H 4-OCH3 H —N(C2H5)2
    I-189 H 4-OCH3 H —N(isoC3H7)2
    I-190 H 4-OCH3 H —N(nC3H7)2
    I-191 H 4-OCH3 H —N(nC4H9)2
    I-192 H 4-CH3 H —N(C6H5)2
    I-193 H 5-OCH3 H —NH—CH3
    I-194 H 5-OCH3 H —NH—CH2—C6H5
    I-195 H 5-OCH3 H —NH-isoC3H7
    I-196 H 5-OCH3 H —NH—C6H5
    I-197 H 5-OCH3 H —NH—C2H5
    I-198 H 5-OCH3 H —NH-nC3H7
    I-199 H 5-OCH3 H —NH-nC4H9
    I-200 H 5-OCH3 H —NH-tertC4H9
    I-201 H 5-OCH3 H —NH-cycloC3H5
    I-202 H 5-OCH3 H —NH-cycloC4H7
    I-203 H 5-OCH3 H —NH-cycloC5H9
    I-204 H 5-OCH3 H —NH-cycloC6H11
    I-205 H 5-OCH3 H —NH-1-adamantyl
    I-206 H 5-OCH3 H —NH-2R-(but-2-y1)
    I-207 H 5-OCH3 H —NH-2S-(but-2-yl)
    I-208 H 5-OCH3 H —NH—O—CH3
    I-209 H 5-OCH3 H —N(CH3)(OCH3)
    I-210 H 5-OCH3 H —N(—(CH2)3—O—)
    I-211 H 5-OCH3 H —N(CH3)2
    I-212 H 5-OCH3 H —N(CH2—C6H5)2
    I-213 H 5-OCH3 H —N(C2H5)2
    I-214 H 5-OCH3 H —N(isoC3H7)2
    I-215 H 5-OCH3 H —N(nC4H9)2
    I-216 H 5-OCH3 H —N(nC4H9)2
    I-217 H 5-OCH3 H —N(C6H5)2
  • [0194]
    Table 2:
  • [0195]
    A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the group —C(O)-G is in position 3 relative to the nitrogen atom and G is of Formula IIg, IIIg or IVg.
    No. RF R1 F R2 F —G
    II-1 H H H —NH—CH3
    II-2 H H H —NH—CH2—C6H5
    II-3 H H H —NH-isoC3H5
    II-4 H H H —NH—C6H5
    II-5 H H H 1,3-Thiazol-2-yl-amide
    II-6 H 4-OCH3 5-OCH3 —NH—CH3
    II-7 H 3-cycloC5H9 H —NH—CH3
    II-8 H H H —NH—C2H5
    II-9 H H H —NH-nC3H7
    II-10 H H H —NH-nC4H9
    II-11 H H H —NH-tertC4H9
    II-12 H H H —NH-cycloC3H5
    II-13 H H H —NH-cycloC4H7
    II-14 H H H —NH-cycloC5H9
    II-15 H H H —NH-cycloC6H11
    II-16 H H H —NH-cycloC7H12
    II-17 H H H —NH—CH3—O—CH3
    II-18 H H H —NH—CH2—CH2—O—CH3
    II-19 H H H —NH-1-adamantyl
    II-20 H H H —NH-(4-HO-C6H5)
    II-21 H H H —NH-(2-CF3—C6H4)
    II-22 H H H —NH-(3-CF3—C6H4)
    II-23 H H H —NH-(4-CF3—C6H4)
    II-24 H H H —NH-(2-OCH3—C6H4)
    II-25 H H H —NH-(3-OCH3—C6H4)
    II-26 H H H —NH-(4-OCH3—C6H4)
    II-27 H H H —NH-(2-SCH3—C6H4)
    II-28 H H H —NH-(3-SCH3—C6H4)
    II-29 H H H —NH-(4-SCH3—C6H4)
    II-30 H H H —NH-(2-N(CH3)2—C6H4)
    II-31 H H H —NH-(3-N(CH3)2—C6H4)
    II-32 H H H —NH-(4-N(CH3)2—C6H4)
    II-33 H H H —NH-(4-CN-C6H4)
    II-34 H H H —NH-(4-Cl-C6H4)
    II-35 H H H —NH-(4-Br-C6H4]
    II-36 H H H —NH-(4-F-C6H4]
    II-37 H H H —NH-(4-CH3—C6H4)
    II-33 H H H —NH-(2-NO2—C6H4)
    II-39 H H H —NH-(3-NO2—C6H4)
    II-40 H H H —NH-(4-NO2—C6H4)
    II-41 H H H —NH-(2,4-OCH3—C6H3)
    II-42 H H H —NH-(3,4-OCH3—C6H3)
    II-43 H H H —NH-(3,4,5-OCH3—C6H2)
    II-44 H H H —NH-(3,4-CH2OCH2—C6H3)
    II-45 H H H —NH-(2,3-CH2OCH2—C6H3)
    II-46 H H H —NH-2-pyridinyl
    II-47 H H H —NH-2-furanyl
    II-48 H H H —NH-2-thienyl
    II-49 H H H —NH-3-pyridinyl
    II-50 H H H —NH-3-furanyl
    II-51 H H H —NH-3-thienyl
    II-52 H H H —NH-4-pyridinyl
    II-53 H H H —NH-2-oxazolyl
    II-54 H H H —NH-3-isoxazolyl
    II-55 H H H —NH-4-isoxazolyl
    II-56 H H H —NH-5-isoxazloyl
    II-57 H H H —NH-2R-(but-2-yl)
    II-58 H H H —NH-2S-(but-2-yl)
    II-59 H H H —NH—O—CH3
    II-60 H H H —N(CH3) (OCH3)
    II-61 H H H —N(—(CH2)3—O—)
    II-62 H H H —NH—O—CH2—C6H5
    II-63 H H H —N(CH3)(O—CH2—C6H5)
    II-64 H H H —N(—(CH2)2—CH(C6H5)—O—)
    II-65 H H H —NH—O—C2H5
    II-66 H H H —N(C2H5)(OC2H5)
    II-67 H H H —N(CH2)(OC2H5)
    II-68 H H H —NH—O-isoC3H7
    II-69 H H H —N(CH3)(O-isoC3H7)
    II-70 H H H —NH—O—nC3H7
    II-71 H H H —N(CH3)(O—nC3H7)
    II-72 H H H —NH—O—nC4H9
    II-73 H H H —N(CH2)(O—nC4H9)
    II-74 H H H —NH-O-tertC4H9
    II-75 H H H —N(CH3)(O-tertC4H9)
    II-76 H H H —NH—O—C6H5
    II-77 H H H —N(CH3)(O—C6H5)
    II-78 H H H —N(CH3)2
    II-79 H H H —N(CH2—C6H5)2
    II-80 H H H —N(C2H5)2
    II-81 H H H —N(isoC3H7)2
    II-82 H H H —N(nC3H7)2
    II-83 H H H —N(nC4H9)2
    II-84 H H H —N(C6H5)2
    II-85 H H H —NH—CH2—CH2—OH
    II-86 H H H —NH—(CH2)3—OH
    II-87 H H H —NH(—(CH2)2CH(C6H5)OH)
    II-88 H H H —NH—(CH2)4—OH
    II-89 H H H —NH(—CH(CH3)—CH2—OH)
    II-90 H H H —NH(—CH2—CH(CH3)—OH)
    II-91 H H H —NH(CH(CH3)(CH2)2OH)
    II-92 H H H —NH(—(CH2)2CH(CH3)OH)
    II-93 H 4-CH3 H —NH—CH3
    II-94 H 4-CH3 H —NH—CH2—C6H5
    II-95 H 4-CH3 H —NH—isoC3H7
    II-96 H 4-CH3 H —NH—C6H5
    II-97 H 4-CH3 H —NH—C2H5
    II-98 H 4-CH3 H —NH-nC3H7
    II-99 H 4-CH3 H —NH—nC4H9
    II-100 H 4-CH3 H —NH-tertC4H9
    II-101 H 4-CH3 H —NH-cycloC3H5
    II-102 H 4-CH3 H —NH- cycloC4H7
    II-103 H 4-CH3 H —NH-cycloC5H9
    II-104 H 4-CH3 H —NH-cycloC6H11
    II-105 H 4-CH3 H —NH-1-adamantyl
    II-106 H 4-CH3 H —NH-2R-(but-2-yl)
    II-107 H 4-CH3 H —NH-2S-(but-2-yl)
    II-108 H 4-CH3 H —NH—O—CH3
    II-109 H 4-CH3 H —N(CH3)(OCH3)
    II-110 H 4-CH3 H —N(—(CH3—O—)
    II-111 H 4-CH3 H —N(CH3)2
    II-112 H 4-CH3 H —N(CH2—C6H5)2
    II-113 H 4-CH3 H —N(C2H5)2
    II-114 H 4-CH3 H —N(isoC3H7)2
    II-115 H 4-CH3 H —N(nC3H7)2
    II-116 H 4-CH3 H —N(nC4H9)2
    II-117 H 4-CH3 H —N(C6H5)2
    II-118 H 5-CH3 H —NH—CH3
    II-119 H 5-CH3 H —NH—CH2—C6H5
    II-120 H 5-CH3 H —NH-isoC3H7
    II-121 H 5-CH3 H —NH-C6H5
    II-122 H 5-CH3 H —NH-C2H5
    II-123 H 5-CH3 H —NH-nC3H7
    II-124 H 5-CH3 H —NH-nC4H9
    II-125 H 5-CH3 H —NH-tertC4H9
    II-126 H 5-CH3 H —NH-cycloC3H5
    II-127 H 5-CH3 H —NH-cycloC4H7
    II-128 H 5-CH3 H —NH-cycloC5H9
    II-129 H 5-CH3 H —NH-cycloC6H11
    II-130 H 5-CH3 H —NH-1-adamantyl
    II-131 H 5-CH3 H —NH-2R-(but-2-yl)
    II-132 H 5-CH3 H —NH-2S-(but-2-yl)
    II-133 H 5-CH3 H —NH—O—CH3
    II-134 H 5-CH3 H —N(CH3)(OCH3)
    II-135 H 5-CH3 H —N(—(CH3)3—O—)
    II-136 H 5-CH3 H —N(CH3)2
    II-137 H 5-CH3 H —N(CH2—C6H5)2
    II-138 H 5-CH3 H —N(C2H5)2
    II-139 H 5-CH3 H —N(isoC3H7)2
    II-140 H 5-CH3 H —N(nC3H7)2
    II-141 H 5-CH3 H —N(nC4H9)2
    II-142 H 5-CH3 H —N(C6H5)2
    II-143 CH3 H H —NH—CH3
    II-144 CH3 H H —NH—CH2—C6H5
    II-145 CH3 H H —NH—isoC3H7
    II-146 CH3 H H —NH-C6H5
    II-147 CH3 H H —NH-C2H5
    II-148 CH3 H H —NH-nC3H7
    II-149 CH3 H H —NH-nC4H9
    II-150 CH3 H H —NH-tertC4H9
    II-151 CH3 H H —NH-cycloC3H5
    II-152 CH3 H H —NH-cycloC4H7
    II-153 CH3 H H —NH-cycloC5H9
    II-154 CH3 H H —NH-cycloC6H11
    II-155 CH3 H H —NH-1-adamantyl
    II-156 CH3 H H —NH-2R-(but-2-yl)
    II-157 CH3 H H —NH-2S-(but-2-yl)
    II-158 CH3 H H —NH—O—CH3
    II-159 CH3 H H —N(CH3)(OCH3)
    II-160 CH3 H H —N(—(CH2)3—O—)
    II-161 CH3 H H —N(CH3)2
    II-162 CH3 H H —N(CH2—C6H5)3
    II-163 CH3 H H —N(C2H5)2
    II-164 CH3 H H —N(isoC3H7)2
    II-165 CH3 H H —N(nC3H7)2
    II-155 CH3 H H —N(nC4H9)2
    II-167 CH3 H H —N(C6H5)2
    II-168 H 4-OCH3 H —NH—CH3
    II-159 H 4-OCH3 H —NH—CH2—C6H5
    II-170 H 4-OCH3 H —NH-isoC3H7
    II-171 H 4-OCH3 H —NH-C6H5
    II-172 H 4-OCH3 H —NH-C2H5
    II-173 H 4-OCH3 H —NH-nC4H7
    II-174 H 4-OCH3 H —NH-nC5H9
    II-175 H 4-OCH3 H —NH-tertC4H9
    II-176 H 4-OCH3 H —NH-cycloC3H5
    II-177 H 4-OCH3 H —NH-cycloC4H7
    II-178 H 4-OCH3 H —NH-cycloC5H9
    II-179 H 4-OCH3 H —NH-cycloC6H11
    II-180 H 4-OCH3 H —NH-1-adamantyl
    II-181 H 4-OCH3 H —NH-2R-(but-2-yl)
    II-182 H 4-OCH3 H —NH-2S-(but-2-yl)
    II-183 H 4-OCH3 H —NH—O—CH3
    II-184 H 4-OCH3 H —N(CH3)(OCH3)
    II-185 H 4-OCH3 H —N(—(CH2)3—O—)
    II-186 H 4-OCH3 H —N(CH3)2
    II-187 H 4-OCH3 H —N(CH2—C6H5)2
    II-188 H 4-OCH3 H —N(C2H5)2
    II-189 H 4-OCH3 H —N(isoC3H7)2
    II-190 H 4-OCH3 H —N(nC3H7)2
    II-191 H 4-OCH3 H —N(nC4H9)2
    II-192 H 4-OCH3 H —N(C6H5)2
    II-193 H 5-OCH3 H —NH—CH3
    II-194 H 5-OCH3 H —NH—CH2—C6H5
    II-195 H 5-OCH3 H —NH-isoC3H7
    II-196 H 5-OCH3 H —NH—C6H5
    II-197 H 5-OCH3 H —NH—C2H5
    II-198 H 5-OCH3 H —NH-nC3H7
    II-199 H 5-OCH3 H —NH-nC4H9
    II-200 H 5-OCH3 H —NH-tertC4H9
    II-201 H 5-OCH3 H —NH-cycloC3H5
    II-202 H 5-OCH3 H —NH-cycloC4H7
    II-203 H 5-OCH3 H —NH-cycloC5H9
    II-204 H 5-OCH3 H —NH-cycloC6H11
    II-205 H 5-OCH3 H —NH-1-adamantyl
    II-206 H 5-OCH3 H —NH-2R-(but-2-y1)
    II-207 H 5-OCH3 H —NH-2S-(but-2-yl)
    II-208 H 5-OCH3 H —NH—O—CH3
    II-209 H 5-OCH3 H —N(CH3)(OCH3)
    II-210 H 5-OCH3 H —N(—(CH2)3—O—)
    II-211 H 5-OCH3 H —N(CH3)2
    II-212 H 5-OCH3 H —N(CH2—C6H5)2
    II-213 H 5-OCH3 H —N(C2H5)2
    II-214 H 5-OCH3 H —N(isoC3H7)2
    II-215 H 5-OCH3 H —N(nC4H9)2
    II-216 H 5-OCH3 H —N(nC4H9)2
    II-217 H 5-OCH3 H —N(C6H5)2
  • [0196]
    Table 3:
  • [0197]
    A is Me2Val, B is Val, D is MeVal, E is Pro, F is of Formula IIf, the substituent —(C═O)-G is in position 4 relative to the nitrogen. G is of Formula IIg, IIIg or IVg.
    No. RF R1 F R2 F —G
    III-1 H H H —NH—CH3
    III-2 H H H —NH—CH2—C6H5
    III-3 H H H —NH-isoC3H5
    III-4 H H H —NH—C6H5
    III-5 H H H 1,3-Thiazol-2-yl-amide
    III-6 H 4-OCH3 5-OCH3 —NH—CH3
    III-7 H 3-cycloC5H9 H —NH—CH3
    III-8 H H H —NH—C2H5
    III-9 H H H —NH-nC3H7
    III-10 H H H —NH-nC4H9
    III-11 H H H —NH-tertC4H9
    III-12 H H H —NH-cycloC3H5
    III-13 H H H —NH-cycloC4H7
    III-14 H H H —NH-cycloC5H9
    III-15 H H H —NH-cycloC6H11
    III-16 H H H —NH-cycloC7H12
    III-17 H H H —NH—CH3—O—CH3
    III-18 H H H —NH—CH2—CH2—O—CH3
    III-19 H H H —NH-1-adamantyl
    III-20 H H H —NH-(4-HO-C6H5)
    III-21 H H H —NH-(2-CF3—C6H4)
    III-22 H H H —NH-(3-CF3—C6H4)
    III-23 H H H —NH-(4-CF3—C6H4)
    III-24 H H H —NH-(2-OCH3—C6H4)
    III-25 H H H —NH-(3-OCH3—C6H4)
    III-26 H H H —NH-(4-OCH3—C6H4)
    III-27 H H H —NH-(2-SCH3—C6H4)
    III-28 H H H —NH-(3-SCH3—C6H4)
    III-29 H H H —NH-(4-SCH3—C6H4)
    III-30 H H H —NH-(2-N(CH3)2—C6H4)
    III-31 H H H —NH-(3-N(CH3)2—C6H4)
    III-32 H H H —NH-(4-N(CH3)2—C6H4)
    III-33 H H H —NH-(4-CN-C6H4)
    III-34 H H H —NH-(4-Cl-C6H4)
    III-35 H H H —NH-(4-Br-C6H4]
    III-36 H H H —NH-(4-F-C6H4]
    III-37 H H H —NH-(4-CH3—C6H4)
    III-33 H H H —NH-(2-NO2—C6H4)
    III-39 H H H —NH-(3-NO2—C6H4)
    III-40 H H H —NH-(4-NO2—C6H4)
    III-41 H H H —NH-(2,4-OCH3—C6H3)
    III-42 H H H —NH-(3,4-OCH3—C6H3)
    III-43 H H H —NH-(3,4,5-OCH3—C6H2)
    III-44 H H H —NH-(3,4-CH2OCH2—C6H3)
    III-45 H H H —NH-(2,3-CH2OCH2—C6H3)
    III-46 H H H —NH-2-pyridinyl
    III-47 H H H —NH-2-furanyl
    III-48 H H H —NH-2-thienyl
    III-49 H H H —NH-3-pyridinyl
    III-50 H H H —NH-3-furanyl
    III-51 H H H —NH-3-thienyl
    III-52 H H H —NH-4-pyridinyl
    III-53 H H H —NH-2-oxazolyl
    III-54 H H H —NH-3-isoxazolyl
    III-55 H H H —NH-4-isoxazolyl
    III-56 H H H —NH-5-isoxazloyl
    III-57 H H H —NH-2R-(but-2-yl)
    III-58 H H H —NH-2S-(but-2-yl)
    III-59 H H H —NH—O—CH3
    III-60 H H H —N(CH3) (OCH3)
    III-61 H H H —N(—(CH2)3—O—)
    III-62 H H H —NH—O—CH2—C6H5
    III-63 H H H —N(CH3)(O—CH2—C6H5)
    III-64 H H H —N(—(CH2)2—CH(C6H5)—O—)
    III-65 H H H —NH—O—C2H5
    III-66 H H H —N(C2H5)(OC2H5)
    III-67 H H H —N(CH2)(OC2H5)
    III-58 H H H —NH—O-isoC3H7
    III-69 H H H —N(CH3)(O-isoC3H7)
    III-70 H H H —NH—O—nC3H7
    III-71 H H H —N(CH3)(O—nC3H7)
    III-72 H H H —NH—O—nC4H9
    III-73 H H H —N(CH2)(O—nC4H9)
    III-74 H H H —NH-O-tertC4H9
    III-75 H H H —N(CH3)(O-tertC4H9)
    III-76 H H H —NH—O—C6H5
    III-77 H H H —N(CH3)(O—C6H5)
    III-78 H H H —N(CH3)2
    III-79 H H H —N(CH2—C6H5)2
    III-80 H H H —N(C2H5)2
    III-81 H H H —N(isoC3H7)2
    III-82 H H H —N(nC3H7)2
    III-83 H H H —N(nC4H9)2
    III-84 H H H —N(C6H5)2
    III-85 H H H —NH—CH2—CH2—OH
    III-86 H H H —NH—(CH2)3—OH
    III-87 H H H —NH(—(CH2)2CH(C6H5)OH)
    III-88 H H H —NH—(CH2)4—OH
    III-89 H H H —NH(—CH(CH3)—CH2—OH)
    III-90 H H H —NH(—CH2—CH(CH3)—OH)
    III-91 H H H —NH(CH(CH3)(CH2)2OH)
    III-92 H H H —NH(—(CH2)2CH(CH3)OH)
    III-93 H 2-CH3 H —NH—CH3
    III-94 H 2-CH3 H —NH—CH2—C6H5
    III-95 H 2-CH3 H —NH—isoC3H7
    III-96 H 2-CH3 H —NH—C6H5
    III-97 H 2-CH3 H —NH—C2H5
    III-98 H 2-CH3 H —NH-nC3H7
    III-99 H 2-CH3 H —NH—nC4H9
    III-100 H 2-CH3 H —NH-tertC4H9
    III-101 H 2-CH3 H —NH-cycloC3H5
    III-102 H 2-CH3 H —NH- cycloC4H7
    III-103 H 2-CH3 H —NH-cycloC5H9
    III-104 H 2-CH3 H —NH-cycloC6H11
    III-105 H 2-CH3 H —NH-1-adamantyl
    III-106 H 2-CH3 H —NH-2R-(but-2-yl)
    III-107 H 2-CH3 H —NH-2S-(but-2-yl)
    III-108 H 2-CH3 H —NH—O—CH3
    III-109 H 2-CH3 H —N(CH3)(OCH3)
    III-110 H 2-CH3 H —N(—(CH3—O—)
    III-111 H 2-CH3 H —N(CH3)2
    III-112 H 2-CH3 H —N(CH2—C6H5)2
    III-113 H 2-CH3 H —N(C2H5)2
    III-114 H 2-CH3 H —N(isoC3H7)2
    III-115 H 2-CH3 H —N(nC3H7)2
    III-116 H 2-CH3 H —N(nC4H9)2
    III-117 H 2-CH3 H —N(C6H5)2
    III-118 H 3-CH3 H —NH—CH3
    III-119 H 3-CH3 H —NH—CH2—C6H5
    III-120 H 3-CH3 H —NH-isoC3H7
    III-121 H 3-CH3 H —NH-C6H5
    III-122 H 3-CH3 H —NH-C2H5
    III-123 H 3-CH3 H —NH-nC3H7
    III-124 H 3-CH3 H —NH-nC4H9
    III-125 H 3-CH3 H —NH-tertC4H9
    III-126 H 3-CH3 H —NH-cycloC3H5
    III-127 H 3-CH3 H —NH-cycloC4H7
    III-128 H 3-CH3 H —NH-cycloC5H9
    III-129 H 3-CH3 H —NH-cycloC6H11
    III-130 H 3-CH3 H —NH-1-adamantyl
    III-131 H 3-CH3 H —NH-2R-(but-2-yl)
    III-132 H 3-CH3 H —NH-2S-(but-2-yl)
    III-133 H 3-CH3 H —NH—O—CH3
    III-134 H 3-CH3 H —N(CH3)(OCH3)
    III-135 H 3-CH3 H —N(—(CH3)3—O—)
    III-136 H 3-CH3 H —N(CH3)2
    III-137 H 3-CH3 H —N(CH2—C6H5)2
    III-138 H 3-CH3 H —N(C2H5)2
    III-139 H 3-CH3 H —N(isoC3H7)2
    III-140 H 3-CH3 H —N(nC3H7)2
    III-141 H 3-CH3 H —N(nC4H9)2
    III-142 H 3-CH3 H —N(C6H5)2
    III-143 CH3 H H —NH—CH3
    III-144 CH3 H H —NH—CH2—C6H5
    III-145 CH3 H H —NH—isoC3H7
    III-146 CH3 H H —NH-C6H5
    III-147 CH3 H H —NH-C2H5
    III-148 CH3 H H —NH-nC3H7
    III-149 CH3 H H —NH-nC4H9
    III-150 CH3 H H —NH-tertC4H9
    III-151 CH3 H H —NH-cycloC3H5
    III-152 CH3 H H —NH-cycloC4H7
    III-153 CH3 H H —NH-cycloC5H9
    III-154 CH3 H H —NH-cycloC6H11
    III-155 CH3 H H —NH-1-adamantyl
    III-156 CH3 H H —NH-2R-(but-2-yl)
    III-157 CH3 H H —NH-2S-(but-2-yl)
    III-158 CH3 H H —NH—O—CH3
    III-159 CH3 H H —N(CH3)(OCH3)
    III-160 CH3 H H —N(—(CH2)3—O—)
    III-161 CH3 H H —N(CH3)2
    III-162 CH3 H H —N(CH2—C6H5)3
    III-163 CH3 H H —N(C2H5)2
    III-164 CH3 H H —N(isoC3H7)2
    III-165 CH3 H H —N(nC3H7)2
    III-166 CH3 H H —N(nC4H9)2
    III-167 CH3 H H —N(C6H5)2
    III-168 H 2-OCH3 H —NH—CH3
    III-169 H 2-OCH3 H —NH—CH2—C6H5
    III-170 H 2-OCH3 H —NH-isoC3H7
    III-171 H 2-OCH3 H —NH-C6H5
    III-172 H 2-OCH3 H —NH-C2H5
    III-173 H 2-OCH3 H —NH-nC4H7
    III-174 H 2-OCH3 H —NH-nC5H9
    III-175 H 2-OCH3 H —NH-tertC4H9
    III-176 H 2-OCH3 H —NH-cycloC3H5
    III-177 H 2-OCH3 H —NH-cycloC4H7
    III-178 H 2-OCH3 H —NH-cycloC5H9
    III-179 H 2-OCH3 H —NH-cycloC6H11
    III-180 H 2-OCH3 H —NH-1-adamantyl
    III-181 H 2-OCH3 H —NH-2R-(but-2-yl)
    III-182 H 2-OCH3 H —NH-2S-(but-2-yl)
    III-183 H 2-OCH3 H —NH—O—CH3
    III-184 H 2-OCH3 H —N(CH3)(OCH3)
    III-185 H 2-OCH3 H —N(—(CH2)3—O—)
    III-186 H 2-OCH3 H —N(CH3)2
    III-187 H 2-OCH3 H —N(CH2—C6H5)2
    III-188 H 2-OCH3 H —N(C2H5)2
    III-189 H 2-OCH3 H —N(isoC3H7)2
    III-190 H 2-OCH3 H —N(nC3H7)2
    III-191 H 2-OCH3 H —N(nC4H9)2
    III-192 H 2-OCH3 H —N(C6H5)2
    III-193 H 3-OCH3 H —NH—CH3
    III-194 H 3-OCH3 H —NH—CH2—C6H5
    III-195 H 3-OCH3 H —NH-isoC3H7
    III-196 H 3-OCH3 H —NH—C6H5
    III-197 H 3-OCH3 H —NH—C2H5
    III-198 H 3-OCH3 H —NH-nC3H7
    III-199 H 3-OCH3 H —NH-nC4H9
    III-200 H 3-OCH3 H —NH-tertC4H9
    III-201 H 3-OCH3 H —NH-cycloC3H5
    III-202 H 3-OCH3 H —NH-cycloC4H7
    III-203 H 3-OCH3 H —NH-cycloC5H9
    III-204 H 3-OCH3 H —NH-cycloC6H11
    III-205 H 3-OCH3 H —NH-1-adamantyl
    III-206 H 3-OCH3 H —NH-2R-(but-2-y1)
    III-207 H 3-OCH3 H —NH-2S-(but-2-yl)
    III-208 H 3-OCH3 H —NH—O—CH3
    III-209 H 3-OCH3 H —N(CH3)(OCH3)
    III-210 H 3-OCH3 H —N(—(CH2)3—O—)
    III-211 H 3-OCH3 H —N(CH3)2
    III-212 H 3-OCH3 H —N(CH2—C6H5)2
    III-213 H 3-OCH3 H —N(C2H5)2
    III-214 H 3-OCH3 H —N(isoC3H7)2
    III-215 H 3-OCH3 H —N(nC4H9)2
    III-216 H 3-OCH3 H —N(nC4H9)2
    III-217 H 3-OCH3 H —N(C6H5)2
  • [0198]
    Table 4:
  • [0199]
    A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the substituent —(C═O)-G is in position 2 relative to the nitrogen. G is of Formula Vg, VIg, VIIg, VIIIg or IXg.
    No. RF R1F R2F -G
    IV-1 H H H —CH3
    IV-2 H H H —C2H5
    IV-3 H H H -nC3H7
    IV-4 H H H -isoC3H7
    IV-5 H H H -nC4H9
    IV-6 H H H -tertC4H9
    IV-7 H H H -cycloC3H5
    IV-8 H H H -cycloC4H7
    IV-9 H H H -cycloC5H9
    IV-10 H H H -cycloC6H11
    IV-11 H H H -cycloC7H12
    IV-12 H H H —CH2—O—CH3
    IV-13 H H H —CH2—CH2—O—CH3
    IV-14 H H H —CH2—C6H5
    IV-15 H H H —C6H5
    IV-16 H H H -(4-HO—C6H5)
    IV-17 H H H -(2-CF3—C6H4)
    IV-18 H H H -(3-CF3—C6H4)
    IV-19 H H H -(4-CF3—C6H4)
    IV-20 H H H -(2-OCH3—C6H4)
    IV-21 H H H -(3-OCH3—C6H4)
    IV-22 H H H -(4-OCH3—C6H4)
    IV-23 H H H -(2-SCH3—C6H4)
    IV-24 H H H -(3-SCH3—C6H4)
    IV-25 H H H -(4-SCH3—C6H4)
    IV-26 H H H -(2-N(CH3)2—C6H4)
    IV-27 H H H -(3-N(CH3)2—C6H4)
    IV-28 H H H -(4-N(CH3)2—C6H4)
    IV-29 H H H -(4-CN—C6H4)
    IV-30 H H H -(4-Cl—C6H4)
    IV-31 H H H -(4-Br—C6H4]
    IV-32 H H H -(4-F—C6H4]
    IV-33 H H H -(4-CH3—C6H4)
    IV-34 H H H -(2-NO2—C6H4)
    IV-35 H H H -(3-NO2—C6H4)
    IV-36 H H H -(4-NO2—C6H4]
    IV-37 H H H -(2,4-OCH3—C6H3)
    IV-38 H H H -(3,4-OCH3—C6H3)
    IV-39 H H H -(3,4,5-OCH3—C6H2)
    IV-40 H H H -(3,4-CH2OCH2—C6H3)
    IV-41 H H H -(2,3-CH2OCH2—C6H3)
    IV-42 H H H -2-pyridinyl
    IV-43 H H H -2-furanyl
    IV-44 H H H -2-thienyl
    IV-45 H H H -3-pyridinyl
    IV-46 H H H -3-furanyl
    IV-47 H H H -3-thienyl
    IV-48 H H H -4-pyridinyl
    IV-49 H H H -2-thiazolyl
    IV-50 H H H -2-oxazolyl
    IV-51 H H H -3-isoxazolyl
    IV-52 H H H -4-isoxazolyl
    IV-53 H H H -5-isoxazolyl
    IV-54 H H H —CF3
    IV-55 H H H —C2F5
    IV-56 H H H —CH3
    IV-57 H H H —C2H5
    IV-58 H H H -nC3H7
    IV-59 H H H -tertC4H9
    IV-60 H H H —CH2—C6H5
    IV-61 H H H —C6H5
    IV-62 H H H —CH2—COOCH3
    IV-63 H H H —CH2—COOC2H5
    IV-64 H H H —CF2—COOCH3
    IV-65 H H H —CF2—COOC2H5
    IV-66 H H H —CH2—CONH2
    IV-67 H H H —CH2—CONHCH3
    IV-68 H H H —CH2—CON(CH3)2
    IV-69 H H H —CH2—CONH—CH2—C6H5
    IV-70 H H H —CH2—CONH—C6H5
    IV-71 H H H —CH2—CONH(CH2—C6H5)2
    IV-72 H H H —CH2—CON(—CH2—CH2
    CH2—CH2—)
    IV-73 H H H —CH2—CON(—CH2—CH2
    CH2—CH2—CH2)
    IV-74 H H H —CH2—CH2—COOCH3
    IV-75 H H H —CH2—CH2—COOC2H5
    IV-76 H H H —CH2—CH2—CONH2
    IV-77 H H H —CH2—CH2—CONHCH3
    IV-78 H H H —CH2—CH2—CON(CH3)2
    IV-79 H H H —CH2—CH2—CONH—CH2—C6H5
    IV-80 H H H —CH2—CH2—CONH—C6H5
    IV-81 H H H —CH2—CH2—CONH(CH2—C6H5)2
    IV-82 H H H —CH2—CH2—CON(—CH2—CH2
    CH2—CH2—)
    IV-83 H H H —CH2—CH2—CON(—CH2
    (CH2)3—CH2)
    IV-84 H H H —CH2—COCH3
    IV-85 H H H —CH2—CH2—COCH3
    IV-86 H H H —CH2—COC2H5
    IV-87 H H H —CH2—CH2—COC2H5
    IV-88 H H H —CH2—CO—C6H5
    IV-89 H H H —CH2—CH2—CO—C6H5
    IV-90 H H H —CH2—CO—CH2—C6H5
    IV-91 H H H —CH2—CH2—CO—CH2—C6H5
    IV-92 H H H —CH2—SOC6H5
    IV-93 H H H —CH2—SOCH3
    IV-94 H H H —CH2SO(4-CH3—C6H4)
    IV-95 H H H —CH2—SO2C6H5
    IV-96 H H H —CH2—SO2CH3
    IV-97 H H H —CH2—SO2(4-CH3—C6H4)
    IV-98 H H H —CH2—CH2—SOC6H5
    IV-99 H H H —CH2—CH2—SOCH3
    IV-100 H H H —CH2—CH2—SO(4-CH3—C6H4)
    IV-101 H H H —CH2—CH2—SO2C6H5
    IV-102 H H H —CH2—CH2—SO2CH3
    IV-103 H H H —CH2—CH2—SO3(4-CH3—C6H4)
    IV-104 CH3 H H —CH3
    IV-105 CH3 H H —C2H5
    IV-106 CH3 H H -nC3H7
    IV-107 CH3 H H -isoC3H7
    IV-108 CH3 H H -nC4H9
    IV-109 CH3 H H -tertC4H9
    IV-110 CH3 H H -cycloC3H5
    IV-111 CH3 H H -cycloC4H7
    IV-112 CH3 H H -cycloC5H9
    IV-113 CH3 H H -cycloC6H11
    IV-114 CH3 H H -cycloC7H12
    IV-115 CH3 H H —CH2—O—CH3
    IV-116 CH3 H H —CH2—CH3—O—CH3
    IV-117 CH3 H H —CH2—C6H5
    IV-118 CH3 H H —C6H5
    IV-119 CH3 H H -(4-HO-C6H5)
    IV-120 CH3 H H -(2-CF3—C6H4)
    IV-121 CH3 H H -(3-CF3—C6H4)
    IV-122 CH3 H H -(4-CF3—C6H4)
    IV-123 CH3 H H -(2-OCH3—C6H4)
    IV-124 CH3 H H -(3-OCH3—C6H4)
    IV-125 CH3 H H -(4-OCH3—C6H4)
    IV-126 CH3 H H -(2-SCH3—C6H4)
    IV-127 CH3 H H -(3-SCH3—C6H4)
    IV-128 CH3 H H -(4-SCH3—C6H4)
    IV-129 CH3 H H -(2-N(CH3)2—C6H4)
    IV-130 CH3 H H -(3-N(CH3)2—C6H4)
    IV-131 CH3 H H -(4-N(CH3)2—C6H4)
    IV-132 CH3 H H -(4-CN-C6H4)
    IV-133 CH3 H H -(4-Cl—C6H4)
    IV-134 CH3 H H -(4-Br—C6H4]
    IV-135 CH3 H H -(4-F—C6H4]
    IV-136 CH3 H H -(4-CH3—C6H4)
    IV-137 CH3 H H -(2-NO2—C6H4)
    IV-138 CH3 H H -(3-NO2—C6H4)
    IV-139 CH3 H H -(4-NO2—C6H4]
    IV-140 CH3 H H -(2,4-OCH3—C6H3)
    IV-141 CH3 H H -(3,4-OCH3—C6H3)
    IV-142 CH3 H H -(3,4,5-OCH3—C6H2)
    IV-143 CH3 H H -(3,4-CH2OCH2—C6H3)
    IV-144 CH3 H H -(2,3-CH2OCH2—C6H3)
    IV-145 CH3 H H -2-pyridinyl
    IV-146 CH3 H H -2-furanyl
    IV-147 CH3 H H -2-thienyl
    IV-148 CH3 H H -3-pyridinyl
    IV-149 CH3 H H -3-furanyl
    IV-150 CH3 H H -3-thienyl
    IV-151 CH3 H H -4-pyridinyl
    IV-152 CH3 H H -2-thiazolyl
    IV-153 CH3 H H -2-oxazolyl
    IV-154 CH3 H H -3-isoxazolyl
    IV-155 CH3 H H -4-isoxazolyl
    IV-156 CH3 H H -5-isoxazoyl
    IV-157 CH3 H H —CF3
    IV-158 CH3 H H —C2F5
    IV-159 CH3 H H —CH3
    IV-160 CH3 H H —C2H5
    IV-161 CH3 H H -nC3H7
    IV-162 CH3 H H -tertC4H9
    IV-163 CH3 H H —CH2—C6H5
    IV-164 CH3 H H —C6H5
    IV-165 CH3 H H —CH2—COOCH3
    IV-166 CH3 H H —CH2—COOC2H5
    IV-167 CH3 H H —CF2—COOCH3
    IV-168 CH3 H H —CF2—COOC2H5
    IV-169 CH3 H H —CH2—CONH2
    IV-170 CH3 H H —CH2—CONHCH3
    IV-171 CH3 H H —CH2—CON(CH3)2
    IV-172 CH3 H H —CH2—CONH—CH2—C6H5
    IV-173 CH3 H H —CH2—CONH—C6H5
    IV-174 CH3 H H —CH2—CONH(CH2—C6H5)2
    IV-175 CH3 H H —CH2—CON(—CH2—CH2
    CH2—CH2—)
    IV-176 CH3 H H —CH2—CON(—CH2—CH2—CH2
    CH2—CH2)
    IV-177 CH3 H H —CH2—CH2—COOCH3
    IV-178 CH3 H H —CH2—CH2—COOC2H5
    IV-179 CH3 H H —CH2—CH2—CONH2
    IV-180 CH3 H H —CH2—CH2—CONHCH3
    IV-181 CH3 H H —CH2—CH2—CON(CH3)2
    IV-182 CH3 H H —CH2—CH2—CONH—CH2—C6H5
    IV-183 CH3 H H —CH2—CH2—CONH—C6H5
    IV-184 CH3 H H —CH2—CH2—CONH(CH2—C6H5)2
    IV-185 CH3 H H —CH2—CH2—CON(—
    CH2—CH2—CH2—CH2—)
    IV-186 CH3 H H —CH2—CH2—CON(—CH2
    (CH2)3—CH2)
    IV-187 CH3 H H —CH2—COCH3
    IV-188 CH3 H H —CH2—CH2—COCH3
    IV-189 CH3 H H —CH2—COC2H5
    IV-190 CH3 H H —CH2—CH2—COC2H5
    IV-191 CH3 H H —CH2—CO—C6H5
    IV-192 CH3 H H —CH2—CH2—CO—C6H5
    IV-193 CH3 H H —CH2—CO—CH2—C6H5
    IV-194 CH3 H H —CH2—CH2—CO—CH2—C6H5
    IV-195 CH3 H H —CH2—SOC6H5
    IV-196 CH3 H H —CH2—SOCH3
    IV-197 CH3 H H —CH2—SO(4-CH3—C6H4)
    IV-198 CH3 H H —CH2—SO2C6H5
    IV-199 CH3 H H —CH2—SO2CH3
    IV-200 CH3 H H —CH2—SO2(4-CH3—C6H4)
    IV-201 CH3 H H —CH2—CH2—SOC6H5
    IV-202 CH3 H H —CH2—CH2—SOCH3
    IV-203 CH3 H H —CH2—CH2—SO(4-CH3—C6H4)
    IV-204 CH3 H H —CH2—CH2—SO2C6H5
    IV-205 CH3 H H —CH2—CH2—SO2CH3
    IV-206 CH3 H H —CH2—CH2—SO2(4-CH3—C6H4)
  • [0200]
    Table 5:
  • [0201]
    A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the substituent —(C═O)-G is in position 3 relative to the nitrogen. G is of Formula Vg, VIg, VIIg, VIIIg or IXg.
    No. RF R1F R2F -G
    V-1 H H H —CH3
    V-2 H H H —C2H5
    V-3 H H H -nC3H7
    V-4 H H H -isoC3H7
    V-5 H H H -nC4H9
    V-6 H H H -tertC4H9
    V-7 H H H -cycloC3H5
    V-8 H H H -cycloC4H7
    V-9 H H H -cycloC5H9
    V-10 H H H -cycloC6H11
    V-11 H H H -cycloC7H12
    V-12 H H H —CH2—O—CH3
    V-13 H H H —CH2—CH2—O—CH3
    V-14 H H H —CH2—C6H5
    V-15 H H H —C6H5
    V-16 H H H -(4-HO—C6H5)
    V-17 H H H -(2-CF3—C6H4)
    V-18 H H H -(3-CF3—C6H4)
    V-19 H H H -(4-CF3—C6H4)
    V-20 H H H -(2-OCH3—C6H4)
    V-21 H H H -(3-OCH3—C6H4)
    V-22 H H H -(4-OCH3—C6H4)
    V-23 H H H -(2-SCH3—C6H4)
    V-24 H H H -(3-SCH3—C6H4)
    V-25 H H H -(4-SCH3—C6H4)
    V-26 H H H -(2-N(CH3)2—C6H4)
    V-27 H H H -(3-N(CH3)2—C6H4)
    V-28 H H H -(4-N(CH3)2—C6H4)
    V-29 H H H -(4-CN—C6H4)
    V-30 H H H -(4-Cl—C6H4)
    V-31 H H H -(4-Br—C6H4]
    V-32 H H H -(4-F—C6H4]
    V-33 H H H -(4-CH3—C6H4)
    V-34 H H H -(2-NO2—C6H4)
    V-35 H H H -(3-NO2—C6H4)
    V-36 H H H -(4-NO2—C6H4]
    V-37 H H H -(2,4-OCH3—C6H3)
    V-38 H H H -(3,4-OCH3—C6H3)
    V-39 H H H -(3,4,5-OCH3—C6H2)
    V-40 H H H -(3,4-CH2OCH2—C6H3)
    V-41 H H H -(2,3-CH2OCH2—C6H3)
    V-42 H H H -2-pyridinyl
    V-43 H H H -2-furanyl
    V-44 H H H -2-thienyl
    V-45 H H H -3-pyridinyl
    V-46 H H H -3-furanyl
    V-47 H H H -3-thienyl
    V-48 H H H -4-pyridinyl
    V-49 H H H -2-thiazolyl
    V-50 H H H -2-oxazolyl
    V-51 H H H -3-isoxazolyl
    V-52 H H H -4-isoxazolyl
    V-53 H H H -5-isoxazolyl
    V-54 H H H —CF3
    V-55 H H H —C2F5
    V-56 H H H —CH3
    V-57 H H H —C2H5
    V-58 H H H -nC3H7
    V-59 H H H -tertC4H9
    V-60 H H H —CH2—C6H5
    V-61 H H H —C6H5
    V-62 H H H —CH2—COOCH3
    V-63 H H H —CH2—COOC2H5
    V-64 H H H —CF2—COOCH3
    V-65 H H H —CF2—COOC2H5
    V-66 H H H —CH2—CONH2
    V-67 H H H —CH2—CONHCH3
    V-68 H H H —CH2—CON(CH3)2
    V-69 H H H —CH2—CONH—CH2—C6H5
    V-70 H H H —CH2—CONH—C6H5
    V-71 H H H —CH2—CONH(CH2—C6H5)2
    V-72 H H H —CH2—CON(—CH2—CH2
    CH2—CH2—)
    V-73 H H H —CH2—CON(—CH2—CH2
    CH2—CH2—CH2)
    V-74 H H H —CH2—CH2—COOCH3
    V-75 H H H —CH2—CH2—COOC2H5
    V-76 H H H —CH2—CH2—CONH2
    V-77 H H H —CH2—CH2—CONHCH3
    V-78 H H H —CH2—CH2—CON(CH3)2
    V-79 H H H —CH2—CH2—CONH—CH2—C6H5
    V-80 H H H —CH2—CH2—CONH—C6H5
    V-81 H H H —CH2—CH2—CONH(CH2—C6H5)2
    V-82 H H H —CH2—CH2—CON(—CH2—CH2
    CH2—CH2—)
    V-83 H H H —CH2—CH2—CON(—CH2
    (CH2)3—CH2)
    V-84 H H H —CH2—COCH3
    V-85 H H H —CH2—CH2—COCH3
    V-86 H H H —CH2—COC2H5
    V-87 H H H —CH2—CH2—COC2H5
    V-88 H H H —CH2—CO—C6H5
    V-89 H H H —CH2—CH2—CO—C6H5
    V-90 H H H —CH2—CO—CH2—C6H5
    V-91 H H H —CH2—CH2—CO—CH2—C6H5
    V-92 H H H —CH2—SOC6H5
    V-93 H H H —CH2—SOCH3
    V-94 H H H —CH2SO(4-CH3—C6H4)
    V-95 H H H —CH2—SO2C6H5
    V-96 H H H —CH2—SO2CH3
    V-97 H H H —CH2—SO2(4-CH3—C6H4)
    V-98 H H H —CH2—CH2—SOC6H5
    V-99 H H H —CH2—CH2—SOCH3
    V-100 H H H —CH2—CH2—SO(4-CH3—C6H4)
    V-101 H H H —CH2—CH2—SO2C6H5
    V-102 H H H —CH2—CH2—SO2CH3
    V-103 H H H —CH2—CH2—SO3(4-CH3—C6H4)
    V-104 CH3 H H —CH3
    V-105 CH3 H H —C2H5
    V-106 CH3 H H -nC3H7
    V-107 CH3 H H -isoC3H7
    V-108 CH3 H H -nC4H9
    V-109 CH3 H H -tertC4H9
    V-110 CH3 H H -cycloC3H5
    V-111 CH3 H H -cycloC4H7
    V-112 CH3 H H -cycloC5H9
    V-113 CH3 H H -cycloC6H11
    V-114 CH3 H H -cycloC7H12
    V-115 CH3 H H —CH2—O—CH3
    V-116 CH3 H H —CH2—CH3—O—CH3
    V-117 CH3 H H —CH2—C6H5
    V-118 CH3 H H —C6H5
    V-119 CH3 H H -(4-HO-C6H5)
    V-120 CH3 H H -(2-CF3—C6H4)
    V-121 CH3 H H -(3-CF3—C6H4)
    V-122 CH3 H H -(4-CF3—C6H4)
    V-123 CH3 H H -(2-OCH3—C6H4)
    V-124 CH3 H H -(3-OCH3—C6H4)
    V-125 CH3 H H -(4-OCH3—C6H4)
    V-126 CH3 H H -(2-SCH3—C6H4)
    V-127 CH3 H H -(3-SCH3—C6H4)
    V-128 CH3 H H -(4-SCH3—C6H4)
    V-129 CH3 H H -(2-N(CH3)2—C6H4)
    V-130 CH3 H H -(3-N(CH3)2—C6H4)
    V-131 CH3 H H -(4-N(CH3)2—C6H4)
    V-132 CH3 H H -(4-CN-C6H4)
    V-133 CH3 H H -(4-Cl—C6H4)
    V-134 CH3 H H -(4-Br—C6H4]
    V-135 CH3 H H -(4-F—C6H4]
    V-136 CH3 H H -(4-CH3—C6H4)
    V-137 CH3 H H -(2-NO2—C6H4)
    V-138 CH3 H H -(3-NO2—C6H4)
    V-139 CH3 H H -(4-NO2—C6H4]
    V-140 CH3 H H -(2,4-OCH3—C6H3)
    V-141 CH3 H H -(3,4-OCH3—C6H3)
    V-142 CH3 H H -(3,4,5-OCH3—C6H2)
    V-143 CH3 H H -(3,4-CH2OCH2—C6H3)
    V-144 CH3 H H -(2,3-CH2OCH2—C6H3)
    V-145 CH3 H H -2-pyridinyl
    V-146 CH3 H H -2-furanyl
    V-147 CH3 H H -2-thienyl
    V-148 CH3 H H -3-pyridinyl
    V-149 CH3 H H -3-furanyl
    V-150 CH3 H H -3-thienyl
    V-151 CH3 H H -4-pyridinyl
    V-152 CH3 H H -2-thiazolyl
    V-153 CH3 H H -2-oxazolyl
    V-154 CH3 H H -3-isoxazolyl
    V-155 CH3 H H -4-isoxazolyl
    V-156 CH3 H H -5-isoxazoyl
    V-157 CH3 H H —CF3
    V-158 CH3 H H —C2F5
    V-159 CH3 H H —CH3
    V-160 CH3 H H —C2H5
    V-161 CH3 H H -nC3H7
    V-162 CH3 H H -tertC4H9
    V-163 CH3 H H —CH2—C6H5
    V-164 CH3 H H —C6H5
    V-165 CH3 H H —CH2—COOCH3
    V-166 CH3 H H —CH2—COOC2H5
    V-167 CH3 H H —CF2—COOCH3
    V-168 CH3 H H —CF2—COOC2H5
    V-169 CH3 H H —CH2—CONH2
    V-170 CH3 H H —CH2—CONHCH3
    V-171 CH3 H H —CH2—CON(CH3)2
    V-172 CH3 H H —CH2—CONH—CH2—C6H5
    V-173 CH3 H H —CH2—CONH—C6H5
    V-174 CH3 H H —CH2—CONH(CH2—C6H5)2
    V-175 CH3 H H —CH2—CON(—CH2—CH2
    CH2—CH2—)
    V-176 CH3 H H —CH2—CON(—CH2—CH2—CH2
    CH2—CH2)
    V-177 CH3 H H —CH2—CH2—COOCH3
    V-178 CH3 H H —CH2—CH2—COOC2H5
    V-179 CH3 H H —CH2—CH2—CONH2
    V-180 CH3 H H —CH2—CH2—CONHCH3
    V-181 CH3 H H —CH2—CH2—CON(CH3)2
    V-182 CH3 H H —CH2—CH2—CONH—CH2—C6H5
    V-183 CH3 H H —CH2—CH2—CONH—C6H5
    V-184 CH3 H H —CH2—CH2—CONH(CH2—C6H5)2
    V-185 CH3 H H —CH2—CH2—CON(—
    CH2—CH2—CH2—CH2—)
    V-186 CH3 H H —CH2—CH2—CON(—CH2
    (CH2)3—CH2)
    V-187 CH3 H H —CH2—COCH3
    V-188 CH3 H H —CH2—CH2—COCH3
    V-189 CH3 H H —CH2—COC2H5
    V-190 CH3 H H —CH2—CH2—COC2H5
    V-191 CH3 H H —CH2—CO—C6H5
    V-192 CH3 H H —CH2—CH2—CO—C6H5
    V-193 CH3 H H —CH2—CO—CH2—C6H5
    V-194 CH3 H H —CH2—CH2—CO—CH2—C6H5
    V-195 CH3 H H —CH2—SOC6H5
    V-196 CH3 H H —CH2—SOCH3
    V-197 CH3 H H —CH2—SO(4-CH3—C6H4)
    V-198 CH3 H H —CH2—SO2C6H5
    V-199 CH3 H H —CH2—SO2CH3
    V-200 CH3 H H —CH2—SO2(4-CH3—C6H4)
    V-201 CH3 H H —CH2—CH2—SOC6H5
    V-202 CH3 H H —CH2—CH2—SOCH3
    V-203 CH3 H H —CH2—CH2—SO(4-CH3—C6H4)
    V-204 CH3 H H —CH2—CH2—SO2C6H5
    V-205 CH3 H H —CH2—CH2—SO2CH3
    V-206 CH3 H H —CH2—CH2—SO2(4-CH3—C6H4)
  • [0202]
    Table 6:
  • [0203]
    A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the substituent —(C═O)-G is in position 4 relative to the nitrogen. G is of Formula Vg, VIg, VIIg, VIIIg or IXg.
    No. RF R1F R2F -G
    VI-1 H H H —CH3
    VI-2 H H H —C2H5
    VI-3 H H H -nC3H7
    VI-4 H H H -isoC3H7
    VI-5 H H H -nC4H9
    VI-6 H H H -tertC4H9
    VI-7 H H H -cycloC3H5
    VI-8 H H H -cycloC4H7
    VI-9 H H H -cycloC5H9
    VI-10 H H H -cycloC6H11
    VI-11 H H H -cycloC7H12
    VI-12 H H H —CH2—O—CH3
    VI-13 H H H —CH2—CH2—O—CH3
    VI-14 H H H —CH2—C6H5
    VI-15 H H H —C6H5
    VI-16 H H H -(4-HO—C6H5)
    VI-17 H H H -(2-CF3—C6H4)
    VI-18 H H H -(3-CF3—C6H4)
    VI-19 H H H -(4-CF3—C6H4)
    VI-20 H H H -(2-OCH3—C6H4)
    VI-21 H H H -(3-OCH3—C6H4)
    VI-22 H H H -(4-OCH3—C6H4)
    VI-23 H H H -(2-SCH3—C6H4)
    VI-24 H H H -(3-SCH3—C6H4)
    VI-25 H H H -(4-SCH3—C6H4)
    VI-26 H H H -(2-N(CH3)2—C6H4)
    VI-27 H H H -(3-N(CH3)2—C6H4)
    VI-28 H H H -(4-N(CH3)2—C6H4)
    VI-29 H H H -(4-CN—C6H4)
    VI-30 H H H -(4-Cl—C6H4)
    VI-31 H H H -(4-Br—C6H4]
    VI-32 H H H -(4-F—C6H4]
    VI-33 H H H -(4-CH3—C6H4)
    VI-34 H H H -(2-NO2—C6H4)
    VI-35 H H H -(3-NO2—C6H4)
    VI-36 H H H -(4-NO2—C6H4]
    VI-37 H H H -(2,4-OCH3—C6H3)
    VI-38 H H H -(3,4-OCH3—C6H3)
    VI-39 H H H -(3,4,5-OCH3—C6H2)
    VI-40 H H H -(3,4-CH2OCH2—C6H3)
    VI-41 H H H -(2,3-CH2OCH2—C6H3)
    VI-42 H H H -2-pyridinyl
    VI-43 H H H -2-furanyl
    VI-44 H H H -2-thienyl
    VI-45 H H H -3-pyridinyl
    VI-46 H H H -3-furanyl
    VI-47 H H H -3-thienyl
    VI-48 H H H -4-pyridinyl
    VI-49 H H H -2-thiazolyl
    VI-50 H H H -2-oxazolyl
    VI-51 H H H -3-isoxazolyl
    VI-52 H H H -4-isoxazolyl
    VI-53 H H H -5-isoxazolyl
    VI-54 H H H —CF3
    VI-55 H H H —C2F5
    VI-56 H H H —CH3
    VI-57 H H H —C2H5
    VI-58 H H H -nC3H7
    VI-59 H H H -tertC4H9
    VI-60 H H H —CH2—C6H5
    VI-61 H H H —C6H5
    VI-62 H H H —CH2—COOCH3
    VI-63 H H H —CH2—COOC2H5
    VI-64 H H H —CF2—COOCH3
    VI-65 H H H —CF2—COOC2H5
    VI-66 H H H —CH2—CONH2
    VI-67 H H H —CH2—CONHCH3
    VI-68 H H H —CH2—CON(CH3)2
    VI-69 H H H —CH2—CONH—CH2—C6H5
    VI-70 H H H —CH2—CONH—C6H5
    VI-71 H H H —CH2—CONH(CH2—C6H5)2
    VI-72 H H H —CH2—CON(—CH2—CH2
    CH2—CH2—)
    VI-73 H H H —CH2—CON(—CH2—CH2
    CH2—CH2—CH2)
    VI-74 H H H —CH2—CH2—COOCH3
    VI-75 H H H —CH2—CH2—COOC2H5
    VI-76 H H H —CH2—CH2—CONH2
    VI-77 H H H —CH2—CH2—CONHCH3
    VI-78 H H H —CH2—CH2—CON(CH3)2
    VI-79 H H H —CH2—CH2—CONH—CH2—C6H5
    VI-80 H H H —CH2—CH2—CONH—C6H5
    VI-81 H H H —CH2—CH2—CONH(CH2—C6H5)2
    VI-82 H H H —CH2—CH2—CON(—CH2
    CH2—CH2—CH2—)
    VI-83 H H H —CH2—CH2—CON(—CH2
    (CH2)3—CH2)
    VI-84 H H H —CH2—COCH3
    VI-85 H H H —CH2—CH2—COCH3
    VI-86 H H H —CH2—COC2H5
    VI-87 H H H —CH2—CH2—COC2H5
    VI-88 H H H —CH2—CO—C6H5
    VI-89 H H H —CH2—CH2—CO—C6H5
    VI-90 H H H —CH2—CO—CH2—C6H5
    VI-91 H H H —CH2—CH2—CO—CH2—C6H5
    VI-92 H H H —CH2—SOC6H5
    VI-93 H H H —CH2—SOCH3
    VI-94 H H H —CH2SO(4-CH3—C6H4)
    VI-95 H H H —CH2—SO2C6H5
    VI-96 H H H —CH2—SO2CH3
    VI-97 H H H —CH2—SO2(4-CH3—C6H4)
    VI-98 H H H —CH2—CH2—SOC6H5
    VI-99 H H H —CH2—CH2—SOCH3
    VI-100 H H H —CH2—CH2—SO(4-CH3—C6H4)
    VI-101 H H H —CH2—CH2—SO2C6H5
    VI-102 H H H —CH2—CH2—SO2CH3
    VI-103 H H H —CH2—CH2—SO3(4-CH3—C6H4)
    VI-104 CH3 H H —CH3
    VI-105 CH3 H H —C2H5
    VI-106 CH3 H H -nC3H7
    VI-107 CH3 H H -isoC3H7
    VI-108 CH3 H H -nC4H9
    VI-109 CH3 H H -tertC4H9
    VI-110 CH3 H H -cycloC3H5
    VI-111 CH3 H H -cycloC4H7
    VI-112 CH3 H H -cycloC5H9
    VI-113 CH3 H H -cycloC6H11
    VI-114 CH3 H H -cycloC7H12
    VI-115 CH3 H H —CH2—O—CH3
    VI-116 CH3 H H —CH2—CH3—O—CH3
    VI-117 CH3 H H —CH2—C6H5
    VI-118 CH3 H H —C6H5
    VI-119 CH3 H H -(4-HO-C6H5)
    VI-120 CH3 H H -(2-CF3—C6H4)
    VI-121 CH3 H H -(3-CF3—C6H4)
    VI-122 CH3 H H -(4-CF3—C6H4)
    VI-123 CH3 H H -(2-OCH3—C6H4)
    VI-124 CH3 H H -(3-OCH3—C6H4)
    VI-125 CH3 H H -(4-OCH3—C6H4)
    VI-126 CH3 H H -(2-SCH3—C6H4)
    VI-127 CH3 H H -(3-SCH3—C6H4)
    VI-128 CH3 H H -(4-SCH3—C6H4)
    VI-129 CH3 H H -(2-N(CH3)2—C6H4)
    VI-130 CH3 H H -(3-N(CH3)2—C6H4)
    VI-131 CH3 H H -(4-N(CH3)2—C6H4)
    VI-132 CH3 H H -(4-CN-C6H4)
    VI-133 CH3 H H -(4-Cl—C6H4)
    VI-134 CH3 H H -(4-Br—C6H4]
    VI-135 CH3 H H -(4-F—C6H4]
    VI-136 CH3 H H -(4-CH3—C6H4)
    VI-137 CH3 H H -(2-NO2—C6H4)
    VI-138 CH3 H H -(3-NO2—C6H4)
    VI-139 CH3 H H -(4-NO2—C6H4]
    VI-140 CH3 H H -(2,4-OCH3—C6H3)
    VI-141 CH3 H H -(3,4-OCH3—C6H3)
    VI-142 CH3 H H -(3,4,5-OCH3—C6H2)
    VI-143 CH3 H H -(3,4-CH2OCH2—C6H3)
    VI-144 CH3 H H -(2,3-CH2OCH2—C6H3)
    VI-145 CH3 H H -2-pyridinyl
    VI-146 CH3 H H -2-furanyl
    VI-147 CH3 H H -2-thienyl
    VI-148 CH3 H H -3-pyridinyl
    VI-149 CH3 H H -3-furanyl
    VI-150 CH3 H H -3-thienyl
    VI-151 CH3 H H -4-pyridinyl
    VI-152 CH3 H H -2-thiazolyl
    VI-153 CH3 H H -2-oxazolyl
    VI-154 CH3 H H -3-isoxazolyl
    VI-155 CH3 H H -4-isoxazolyl
    VI-156 CH3 H H -5-isoxazoyl
    VI-157 CH3 H H —CF3
    VI-158 CH3 H H —C2F5
    VI-159 CH3 H H —CH3
    VI-160 CH3 H H —C2H5
    VI-161 CH3 H H -nC3H7
    VI-162 CH3 H H -tertC4H9
    VI-163 CH3 H H —CH2—C6H5
    VI-164 CH3 H H —C6H5
    VI-165 CH3 H H —CH2—COOCH3
    VI-166 CH3 H H —CH2—COOC2H5
    VI-167 CH3 H H —CF2—COOCH3
    VI-168 CH3 H H —CF2—COOC2H5
    VI-169 CH3 H H —CH2—CONH2
    VI-170 CH3 H H —CH2—CONHCH3
    VI-171 CH3 H H —CH2—CON(CH3)2
    VI-172 CH3 H H —CH2—CONH—CH2—C6H5
    VI-173 CH3 H H —CH2—CONH—C6H5
    VI-174 CH3 H H —CH2—CONH(CH2—C6H5)2
    VI-175 CH3 H H —CH2—CON(—CH2—CH2
    CH2—CH2—)
    VI-176 CH3 H H —CH2—CON(—CH2—CH2—CH2
    CH2—CH2)
    VI-177 CH3 H H —CH2—CH2—COOCH3
    VI-178 CH3 H H —CH2—CH2—COOC2H5
    VI-179 CH3 H H —CH2—CH2—CONH2
    VI-180 CH3 H H —CH2—CH2—CONHCH3
    VI-181 CH3 H H —CH2—CH2—CON(CH3)2
    VI-182 CH3 H H —CH2—CH2—CONH—CH2—C6H5
    VI-183 CH3 H H —CH2—CH2—CONH—C6H5
    VI-184 CH3 H H —CH2—CH2—CONH(CH2—C6H5)2
    VI-185 CH3 H H —CH2—CH2—CON(—
    CH2—CH2—CH2—CH2—)
    VI-186 CH3 H H —CH2—CH2—CON(—CH2
    (CH2)3—CH2)
    VI-187 CH3 H H —CH2—COCH3
    VI-188 CH3 H H —CH2—CH2—COCH3
    VI-189 CH3 H H —CH2—COC2H5
    VI-190 CH3 H H —CH2—CH2—COC2H5
    VI-191 CH3 H H —CH2—CO—C6H5
    VI-192 CH3 H H —CH2—CH2—CO—C6H5
    VI-193 CH3 H H —CH2—CO—CH2—C6H5
    VI-194 CH3 H H —CH2—CH2—CO—CH2—C6H5
    VI-195 CH3 H H —CH2—SOC6H5
    VI-196 CH3 H H —CH2—SOCH3
    VI-197 CH3 H H —CH2—SO(4-CH3—C6H4)
    VI-198 CH3 H H —CH2—SO2C6H5
    VI-199 CH3 H H —CH2—SO2CH3
    VI-200 CH3 H H —CH2—SO2(4-CH3—C6H4)
    VI-201 CH3 H H —CH2—CH2—SOC6H5
    VI-202 CH3 H H —CH2—CH2—SOCH3
    VI-203 CH3 H H —CH2—CH2—SO(4-CH3—C6H4)
    VI-204 CH3 H H —CH2—CH2—SO2C6H5
    VI-205 CH3 H H —CH2—CH2—SO2CH3
    VI-206 CH3 H H —CH2—CH2—SO2(4-CH3—C6H4)
  • [0204]
    Table 7:
  • [0205]
    A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIIf, the substituent —(C═O)-G is in position 2 relative to the nitrogen and af is 1. G is of Formula IIg or IIIg. The compounds are mixtures of diasteromers, configuration in F is R, S (cis) or S,R (cis).
    No. Rf -G
    VII-1 H —NH—CH3
    VII-2 H —NH—CH2—C6H5
    VII-3 H —NH-isoC3H7
    VII-4 H —NH—C6H5
    VII-5 H 1,3-Thiazol-2-yl-amide
    VII-6 H —NH—CH3
    VII-7 H —NH—CH3
    VII-8 H —NH—C2H5
    VII-9 H —NH-nC3H7
    VII-10 H —NH-nC4H9
    VII-11 H —NH-tertC4H9
    VII-12 H —NH-cycloC3H5
    VII-13 H —NH-cycloC4H7
    VII-14 H —NH-cycloC5H9
    VII-15 H —NH-cycloC6H11
    VII-16 H —NH-cycloC7H12
    VII-17 H —NH—CH2—O—CH3
    VII-18 H —NH—CH2—CH2—O—CH3
    VII-19 H —NH-1-adamantyl
    VII-20 H —NH-(4-HO—C6H5)
    VII-21 H —NH-(2-CF3—C6H4)
    VII-22 H —NH-(3-CF3—C4H4)
    VII-23 H —NH-(4-CF3—C6H4)
    VII-24 H —NH-(2-OCH3—C6H4)
    VII-25 H —NH-(3-OCH3—C6H4)
    VII-26 H —NH-(4-OCH3—C6H4)
    VII-27 H —NH-(2-SCH3—C6H4)
    VII-28 H —NH-(3-SCH3—C6H4)
    VII-29 H —NH-(4-SCH3—C6H4)
    VII-30 H —NH-(2-N(CH3)2—C6H4)
    VII-31 H —NH-(3-N(CH3)2—C6H4)
    VII-32 H —NH-(4-N(CH3)2—C6H4)
    VII-33 H —NH-(4-CN—C6H4)
    VII-34 H —NH-(4-Cl—C6H4)
    VII-35 H —NH-(4-Br—C6H4]
    VII-36 H —NH-(4-F—C6H4]
    VII-37 H —NH-(4-CH3—C6H4)
    VII-38 H —NH-(2-NO2—C6H4)
    VII-39 H —NH-(3-NO2—C6H4)
    VII-40 H —NH-(4-NO2—C6H4]
    VII-41 H —NH-(2,4-OCH3—C6H3)
    VII-42 H —NH-(3,4-OCH3—C6H3)
    VII-43 H —NH-(3,4,5-OCH3—C6H2)
    VII-44 H —NH-(3,4-CH2OCH2—C6H3)
    VII-45 H —NH-(2,3-CH2OCH2—C6H3)
    VII-46 H —NH-2-pyridinyl
    VII-47 H —NH-2-furanyl
    VII-48 H —NH-2-thienyl
    VII-49 H —NH-3-pyridinyl
    VII-50 H —NH-3-furanyl
    VII-51 H —NH-3-thienyl
    VII-52 H —NH-4-pyridinyl
    VII-53 H —NH-2-oxazolyl
    VII-54 H —NH-3-isoxazolyl
    VII-55 H —NH-4-isoxazolyl
    VII-56 H —NH-5-isoxazoyl
    VII-57 H —NH-2R-(but-2-yl)
    VII-58 H —NH-2S-(but-2-yl)
    VII-59 H —NH—O—CH3
    VII-60 H —N(CH3)(OCH3)
    VII-61 H —N(—(CH2)3—O—)
    VII-62 H —NH—O—CH2—C6H5
    VII-63 H —N(CH3)(O—CH2—C6H5)
    VII-64 H —N(—(CH2)2—CH(C6H5)—O—)
    VII-65 H —NH—O—C2H5
    VII-66 H —N(C2H5)(OC2H5)
    VII-67 H —N(CH3)(OC2H5)
    VII-68 H —NH—O-isoC3H7
    VII-69 H —N(CH3)(O-isoC3H7)
    VII-70 H —NH—O-nC3H7
    VII-71 H —N(CH3)(O-nC3H7)
    VII-72 H —NH—O-nC4H9
    VII-73 H —N(CH3)(O-nC4H9)
    VII-74 H —NH—O-tertC4H9
    VII-75 H —N(CH3)(O-tertC4H9)
    VII-76 H —NH—O—C6H5
    VII-77 H —N(CH3)(O—C6H5)
    VII-78 H —N(CH3)2
    VII-79 H —N(CH2—C6H5)2
    VII-80 H —N(C2H5)2
    VII-81 H —N(isoC3H7)2
    VII-82 H —N(nC3H7)2
    VII-83 H —N(nC4H9)2
    VII-84 H —N(C6H5)2
    VII-85 H —NH—CH2—CH2—OH
    VII-86 H —NH—(CH2)3—OH
    VII-87 H —NH(—(CH2)2—CH(C6H5)—OH)
    VII-88 H —NH—(CH2)4—OH
    VII-89 H —NH(—CH(CH3)—CH2—OH)
    VII-90 H —NH(—CH2—CH(CH3)—OH)
    VII-91 H —NH(—CH(CH3)—(CH2)2—OH)
    VII-92 H —NH(—(CH2)2—CH(CH3)—OH)
    VII-93 CH3 —NH—CH3
    VII-94 CH3 —NH—CH2—C6H5
    VII-95 CH3 —NH-isoC3H7
    VII-96 CH3 —NH—C6H5
    VII-97 CH3 —NH—C2H5
    VII-98 CH3 —NH-nC3H7
    VII-99 CH3 —NH-nC4H9
    VII-100 CH3 —NH-tertC4H9
    VII-101 CH3 —NH-cycloC3H5
    VII-102 CH3 —NH-cycloC4H7
    VII-103 CH3 —NH-cycloC5H9
    VII-104 CH3 —NH-cycloC6H11
    VII-105 CH3 —NH-1-adamantyl
    VII-106 CH3 —NH-2R-(but-2-yl)
    VII-107 CH3 —NH-2S-(but-2-yl)
    VII-108 CH3 —NH—O—CH3
    VII-109 CH3 —N(CH3)(OCH3)
    VII-110 CH3 —N(—(CH2)3—O—)
    VII-111 CH3 —N(CH3)2
    VII-112 CH3 —N(CH2—C6H5)2
    VII-113 CH3 —N(C2H5)2
    VII-114 CH3 —N(isoC3H7)2
    VII-115 CH3 —N(nC3H7)2
    VII-116 CH3 —N(nC4H9)2
    VII-117 CH3 —N(C6H5)2
  • [0206]
    Table 8:
  • [0207]
    A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIIf, the substituent —(C═O)-G is in position 2 relative to the nitrogen and af is 1. G is of Formula IIg or IIIg.
  • [0208]
    The compounds are mixtures of diasteromers, configuration in F is either R, R (trans) or S,S (trans).
    No. Rf -G
    VIII-1 H —NH—CH3
    VIII-2 H —NH—CH2—C6H5
    VIII-3 H —NH-isoC3H7
    VIII-4 H —NH—C6H5
    VIII-5 H 1,3-Thiazol-2-yl-amide
    VIII-6 H —NH—CH3
    VIII-7 H —NH—CH3
    VIII-8 H —NH—C2H5
    VIII-9 H —NH-nC3H7
    VIII-10 H —NH-nC4H9
    VIII-11 H —NH-tertC4H9
    VIII-12 H —NH-cycloC3H5
    VIII-13 H —NH-cycloC4H7
    VIII-14 H —NH-cycloC5H9
    VIII-15 H —NH-cycloC6H11
    VIII-16 H —NH-cycloC7H12
    VIII-17 H —NH—CH2-O-CH3
    VIII-18 H —NH—CH2—CH2—O-CH3
    VIII-19 H —NH-1-adamantyl
    VIII-20 H —NH-(4-HO-C6H5)
    VIII-21 H —NH-(2-CF3—C6H4)
    VIII-22 H —NH-(3-CF3—C6H4)
    VIII-23 H —NH-(4-CF3—C6H4)
    VIII-24 H —NH-(2-OCH3—C6H4)
    VIII-25 H —NH-(3-OCH3—C6H4)
    VIII-26 H —NH-(4-OCH3—C6H4)
    VIII-27 H —NH-(2-SCH3—C6H4)
    VIII-28 H —NH-(3-SCH3—C6H4)
    VIII-29 H —NH-(4-SCH3—C6H4)
    VIII-30 H —NH-(2-N(CH3)2—C6H4)
    VIII-31 H —NH-(3-N(CH3)2-C6H4)
    VIII-32 H —NH-(4-N(CH3)2-C6H4)
    VIII-33 H —NH-(4-CN-C6H4)
    VIII-34 H —NH-(4-Cl-C6H4)
    VIII-35 H —NH-(4-Br-C6H4]
    VIII-36 H —NH-(4-F-C-6H4]
    VIII-37 H —NH-(4-CH3-C6H4)
    VIII-38 H —NH-(2-NO2-C4H4)
    VIII-39 H —NH-(3-NO2-C6H4)
    VIII-40 H —NH-(4-NO2-C6H4]
    VIII-41 H —NH-(2,4-OCH3-C6H3)
    VIII-42 H —NH-(3,4-OCH3-C6H3)
    VIII-43 H —NH-(3,4,5-OCH3-C6H2)
    VIII-44 H —NH-(3,4-CH2OCH2-C6H3)
    VIII-45 H —NH-(2,3-CH2OCH2-C6H3)
    VIII-46 H —NH-2-pyridinyl
    VIII-47 H —NH-2-furanyl
    VIII-48 H —NH-2-thienyl
    VIII-49 H —NH-3-pyridinyl
    VIII-50 H —NH-3-furanyl
    VIII-51 H —NH-3-thienyl
    VIII-52 H —NH-4-pyridinyl
    VIII-53 H —NH-2-oxazolyl
    VIII-54 H —NH-3-isoxazolyl
    VIII-55 H —NH-4-isoxazolyl
    VIII-56 H —NH-5-isoxazoyl
    VIII-57 H —NH-2R-(but-2-yl)
    VIII-58 H —NH-2S-(but-2-yl)
    VIII-59 H —NH—O—CH3
    VIII-60 H —N(CH3) (OCH3)
    VIII-61 H —N(—(CH2)3—O—)
    VIII-62 H —NH—O—CH2—C6H5
    VIII-63 H —N(CH3) (O—CH2—C6H5)
    VIII-64 H —N(—(CH2)2—CH(C6H5)—O—)
    VIII-65 H —NH—O—C2H5
    VIII-66 H —N(C2H5) (OC2H5)
    VIII-67 H —N(CH3) (OC2H5)
    VIII-68 H NH—O-isoC3H7
    VIII-69 H —N(CH3) (O-isoC3H7)
    VIII-70 H —NH—O-nC3H7
    VIII-71 H —N(CH3) (O-nC3H7)
    VIII-72 H —NH—O-nC4H9
    VIII-73 H —N(CH3) (O-nC4H9)
    VIII-74 H —NH—O-tertC4H9
    VIII-75 H —N(CH3) (O-tertC4H9)
    VIII-76 H —NH—O—C6H5
    VIII-77 H —N(CH3) (O—C6H5)
    VIII-78 H —N(CH3)2
    VIII-79 H —N(CH2—C6H5)2
    VIII-80 H —N(C2H5)2
    VIII-81 H —N(isoC3H7)2
    VIII-82 H —N(nC3H7)2
    VIII-83 H —N(nC4H9)2
    VIII-84 H —N(C6H5)2
    VIII-85 H —NH—CH2—CH2—OH
    VIII-86 H —NH—(CH2)3—OH
    VIII-87 H —NH(—(CH2)2—CH(C6H5) —OH)
    VIII-88 H —NH—(CH2)4—OH
    VIII-89 H —NH(—CH(CH3)—CH2—OH)
    VIII-90 H —NH(—CH2CH(CH3) —OH)
    VIII-91 H —NH(—CH(CH3)—(CH2)2OH)
    VIII-92 H —NH(—(CH2)2—CH(CH3)—OH)
    VIII-93 CH3 —NH—CH3
    VIII-94 CH3 —NH—CH2—C6H5
    VIII-95 CH3 —NH-isoC3H7
    VIII-96 CH3 —NH—C6H5
    VIII-97 CH3 —NH—C2H5
    VIII-98 CH3 —NH-nC3H7
    VIII-99 CH3 —NH-nC4H9
    VIII-100 CH3 —NH-tertC4H9
    VIII-101 CH3 —NH-cycloC3H5
    VIII-102 CH3 —NH-cycloC4H7
    VIII-103 CH3 —NH-cycloC5H9
    VIII-104 CH3 —NH-cycloC6H11
    VIII-105 CH3 —NH-1-adamantyl
    VIII-106 CH3 —NH-2R-(but-2-yl)
    VIII-107 CH3 —NH-2S-(but-2-yl)
    VIII-108 CH3 —NH—O—CH3
    VIII-109 CH3 —N(CH3) (OCH3)
    VIII-110 CH3 —N(—(CH2)3—O—)
    VIII-111 CH3 —N(CH3)2
    VIII-112 CH3 —N(CH2—C6H5)2
    VIII-113 CH3 —N(C2H5)2
    VIII-114 CH3 —N(isoC3H7)2
    VIII-115 CH3 —N(nC3H7)2
    VIII-116 CH3 —N(nC4H9)2
    VIII-117 CH3 —N(C6H5)2
  • [0209]
    Mass spectrometry data of selected examples:
    I-1 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHCH3
    FAB-MS: 588 (M + H+)
    I-2 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHCH2C6H5
    FAB-MS: 664 (M + H+)
    I-3 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHCH(CH3)2
    FAB-MS: 616 (M + H+)
    I-4 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHC6H5
    FAB-MS: 650 (M + H+)
    I-5 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NH(thiazol-2-yl)
    FAB-MS: 657 (M + H+)
    I-6 2(Me2Val-Val-MeVal-ProNH)-4, 5-bis(methoxy)C6H2C(O)NHCH3
    FAB-MS: 649 (M + H+)
    I-7 2-(Me2ValVal-MeVal-ProNH)-3-cyclopentanyl-C6H3C(O)NHCH3
    FAB-MS: 656 (M + H+)
    I-64 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—N(—(CH2)2
    CH(C6H5)O—)
    (mix. of diastereomers) FAB-MS: 706 (M + H+)
    I-79 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—N(CH2C6H5)2
    FAB-MS: 754 (M +H+)
    I-86 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—NH—(—(CH2)3
    OH)
    FAB-MS: 632 (M + H+)
    I-87 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NH((CH2)2CH(C6H5)
    OH)
    FAB-MS: 708 (M + H+)
    I-143 2-(Me2Val-Val-MeVal-Pro-N(CH3))—C6H4—CONHCH3
    FAB-MS: 601 (M + H+)
    II-1 3-(Ne2Val-Val-MeVal-Pro-NH)—C6H4—CO—NHCH3
    FAB-MS: 588 (M + H+)
    II-2 3-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—NH CH2C6H5
    FAB-MS: 664 (M + H+)
    IV-1 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—CH3
    FAB-MS: 609 (M + H+)
    IV-15 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—C6H5
    FAB-MS: 635 (M + H+)
  • Evaluation of Biological Activity
  • [0210]
    In Vitro Methodology
  • [0211]
    Cytotoxicity was measured using a standard methodology for adherent cell lines, such as the microculture tetrazolium assay (MTT). Details of this assay have been published (Alley, M. C. et al., Cancer Research 48: 589-601, 1988). Exponentially growing cultures of tumor cells such as the HT-29 colon carcinoma or LX-1 lung tumor were used to make microtiter plate cultures. Cells were seeded at 5000-20,000 cells per well in 96-well plates (in 150 mL of media), and grown overnight at 37° C. Test compounds were added, in 10-fold dilutions varying from 10−4 M to 10−10 M. Cells were then incubated for 48 hours. To determine the number of viable cells in each well, the MTT dye was added (50 mL of a 3 mg/mL solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in saline). This mixture was incubated at 37° C. for 5 hours, and then 50 mL of 25% SDS, pH 2, was added to each well. After an overnight incubation, the absorbance of each well at 550 nm was read using an ELISA reader. The values for the mean+/−SD of data from replicated wells were calculated, using the formula % T/C (% viable cells treated/control). The concentration of test compound which gives a T/C of 50% growth inhibition was designated as the IC50.
    Compound No. IC50 (mol/l)
    I-1   4 × 10−7
    I-2 >10−6
    I-3   5 × 10−7
    I-4   4 × 10−7
    I-5 1.5 × 10−7
    I-6   2 × 10−7
    I-7   4 × 10−7
    I-60   4 × 10−7
    I-64 2.5 × 10−7
    I-86   6 × 10−7
    I-87   2 × 10−7
    II-1 >10−6
    II-2 >10−6
    IV-1 >10−6
    IV-15   7 × 10−8
    VII-2 >10−6
  • [0212]
    In Vivo Methodology
  • [0213]
    Compounds of this invention may be further tested in any of the various preclinical assays for in vivo activity which are indicative of clinical utility. Such assays are conducted with nude mice into which tumor tissue, preferably of human origin, has been transplanted (“xenografted”), as is well known in this field. Test compounds are evaluated for their anti-tumor efficacy following administration to the xenograft-bearing mice.
  • [0214]
    More specifically, human tumors which have been grown in athymic nude mice are transplanted into new recipient animals, using tumor fragments which are about 50 mg in size. The day of transplantation is designated as day 0. Six to ten days later, the mice are treated with the test compounds given as an intravenous or intraperitoneal injection, in groups of 5-10 mice at each dose. Compounds are given daily for 5 days, 10 days or 15 days, at doses from 10-100 mg/kg body weight. Tumor diameters and body weights are measured twice weekly. Tumor masses are calculated using the diameters measured with Vernier calipers, and the formula:
  • (length×width2)/2=mg of tumor weight
  • [0215]
    Mean tumor weights are calculated for each treatment group, and T/C values determined for each group relative to the untreated control tumors.
  • [0216]
    The novel compounds of the present invention show good in vitro activity in the above-mentioned assay system.
  • Equivalents
  • [0217]
    While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US5857 *Oct 17, 1848 Flood-fence
US5860 *Oct 17, 1848 peters
US13071 *Jun 12, 1855AJoshua turner
US29177 *Jul 17, 1860 Improvement in planishing copper vessels
US29258 *Jul 24, 1860 Improvement in capstans for ditching-plows
US32091 *Apr 16, 1861 Improvement in corn-planters
US35506 *Jun 10, 1862 Improvement in parlor-stoves
US42772 *May 17, 1864 Improvement in apparatus for distilling off gases, and vapors
US49617 *Aug 29, 1865 Inkstand
US49818 *Sep 5, 1865 Improvement in seeding-machines
US52764 *Feb 20, 1866 Improved machine for extracting essential oils
US54115 *Apr 24, 1866 Improved hair-curling fluid
US55861 *Jun 26, 1866 Improvement in machines for fine-cutting tobiacco
US69077 *Sep 24, 1867Josiah CopleyJosiah copley
US4346442 *Jul 29, 1980Aug 24, 1982Merrill Lynch, Pierce, Fenner & Smith IncorporatedSecurities brokerage-cash management system
US4648037 *Mar 15, 1984Mar 3, 1987Metropolitan Life Insurance CompanyMethod and apparatus for benefit and financial communication
US4750121 *Oct 3, 1985Jun 7, 1988Halley Gustavo MPension benefits system
US4969094 *May 22, 1989Nov 6, 1990Pension Benefits System TrustSelf-implementing pension benefits system
US5136502 *Oct 2, 1991Aug 4, 1992Fred Van RemortelSystem for funding, analyzing and managing health care liabilities
US5429506 *Apr 5, 1993Jul 4, 1995Westport Management Services, Inc.Method of computerized administration of a life insurance plan using computerized administration supervisory system
US5590037 *Sep 17, 1993Dec 31, 1996The Evergreen Group IncorporatedDigital computer system and methods for computing a financial projection and an illustration of a prefunding program for an employee benefit
US5897620 *Jul 8, 1997Apr 27, 1999Priceline.Com Inc.Method and apparatus for the sale of airline-specified flight tickets
US5913198 *Sep 9, 1997Jun 15, 1999Sbp Services, Inc.System and method for designing and administering survivor benefit plans
US5960411 *Sep 12, 1997Sep 28, 1999Amazon.Com, Inc.Method and system for placing a purchase order via a communications network
US5966693 *May 7, 1996Oct 12, 1999Money Accumulation Programs, Inc.Method for combining loan with key employee life insurance
US5970478 *Mar 12, 1997Oct 19, 1999Walker Asset Management Limited PartnershipMethod, apparatus, and program for customizing credit accounts
US6092047 *Oct 7, 1997Jul 18, 2000Benefits Technologies, Inc.Apparatus and method of composing a plan of flexible benefits
US6154732 *Jul 25, 1997Nov 28, 2000Guidedchoice.ComSystem for providing investment advice and management of pension assets
US6322125 *Dec 12, 2000Nov 27, 2001Cordell Eric BauerTruck bed extension
US6370571 *Mar 5, 1997Apr 9, 2002At Home CorporationSystem and method for delivering high-performance online multimedia services
US6389457 *Feb 13, 2001May 14, 2002Research In Motion LimitedSystem and method for pushing information from a host system to a mobile data communication device
US6401079 *Oct 1, 1999Jun 4, 2002Inleague, Inc.System for web-based payroll and benefits administration
US6401113 *Feb 13, 2001Jun 4, 2002Research In Motion LimitedSystem and method for pushing information from a host system to a mobile data communication device
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6884869Nov 1, 2001Apr 26, 2005Seattle Genetics, Inc.Pentapeptide compounds and uses related thereto
US7012100Jun 4, 2002Mar 14, 2006Avolix Pharmaceuticals, Inc.Cell migration inhibiting compositions and methods and compositions for treating cancer
US7098308Nov 1, 2004Aug 29, 2006Seattle Genetics, Inc.Pentapeptide compounds and uses related thereto
US7256257Apr 30, 2002Aug 14, 2007Seattle Genetics, Inc.Pentapeptide compounds and uses related thereto
US7423116Jun 12, 2006Sep 9, 2008Seattle Genetics Inc.Pentapeptide compounds and uses related thereto
US7659241Jul 31, 2003Feb 9, 2010Seattle Genetics, Inc.Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7700615Feb 1, 2006Apr 20, 2010Avolix Pharmaceuticals, Inc.Cell migration inhibiting compositions and methods and compositions for treating cancer
US7745394Aug 3, 2007Jun 29, 2010Seattle Genetics, Inc.Monomethylvaline compounds capable of conjugation to ligands
US7829531Mar 20, 2009Nov 9, 2010Seattle Genetics Inc.Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7851437Nov 18, 2009Dec 14, 2010Seattle Genetics Inc.Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US8557780Apr 29, 2011Oct 15, 2013Seattle Genetics, Inc.Monomethylvaline compounds capable of conjugation to ligands
US8703714Apr 29, 2011Apr 22, 2014Seattle Genetics, Inc.Monomethylvaline compounds capable of conjugation to ligands
US8906376Sep 10, 2010Dec 9, 2014Seattle Genetics, Inc.Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040157782 *Apr 30, 2002Aug 12, 2004Svetlana DoroninaPentapeptide compounds and uses related thereto
US20050009751 *Nov 1, 2001Jan 13, 2005Seattle Genetics, Inc.Pentapeptide compounds and uses related thereto
US20050107289 *Jul 6, 2004May 19, 2005The Scripps Research InstituteAnti-microbial peptides and compositions
US20050113308 *Nov 1, 2004May 26, 2005Seattle Genetics, Inc.Pentapeptide compounds and uses related thereto
US20060074008 *Jul 31, 2003Apr 6, 2006Senter Peter DDrug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20060128742 *Feb 1, 2006Jun 15, 2006Avolix Pharmaceuticals, Inc.Cell migration inhibiting compositions and methods and compositions for treating cancer
US20090324621 *Mar 20, 2009Dec 31, 2009Seattle Genetics, Inc.Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004010957A3 *Jul 31, 2003Jun 10, 2004Seattle Genetics IncDrug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004052916A2 *Dec 5, 2003Jun 24, 2004Adaptive Therapeutics, Inc.Novel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids
WO2004052916A3 *Dec 5, 2003Sep 16, 2004Adaptive Therapeutics IncNovel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids
Classifications
U.S. Classification514/19.3, 530/330
International ClassificationA61P35/00, A61K35/56, A61K38/00, C07K5/103, C07K5/117, C07K7/02
Cooperative ClassificationC07K5/101, C07K5/1024, A61K38/00, C07K7/02
European ClassificationC07K7/02, C07K5/10A1B, C07K5/10H